Anti-CD33 antibodies and uses thereof

Abstract

The subject matter disclosed herein provides antibodies or antigen-binding fragments thereof that bind to CD33, and methods of using such antibodies or antigen-binding fragments thereof. In certain embodiments, the CD33 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:18, SEQ ID NO:28, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:72, SEQ ID NO:81, or SEQ ID NO:88.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 240,220, filed September 2, 2021, the contents of which are incorporated by reference in their entirety and priority thereto is claimed.

[0002] Sequence Listing This application contains a Sequence Listing submitted via EFS-Web, which is incorporated herein by reference in its entirety. The Sequence Listing, created on August 31, 2022, is named 0727341389.xml and is 102,312 bytes in size.

[0003] 1. Field of the invention The subject matter disclosed herein relates to antibodies that bind to CD33 and methods of using such antibodies. [Background technology]

[0004] 2. Background of the invention Acute myeloid leukemia (AML) is the most common and most lethal form of acute leukemia in the United States. For the past 40 years, the standard of care has been chemotherapy, but in recent years, CD33 antibody-drug conjugates (ADCs) and targeted small molecules have been added to the suite. Despite these new additions, AML remains a devastating disease with a 5-year survival rate of less than 30%. Thus, there is a significant need for novel AML interventions.

[0005] Given the important role for CD33 in disease (eg, AML), antibodies that bind to CD33 and methods of using such agents are desirable. Summary of the Invention

[0006] 3. Overview of the Invention The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that specifically bind to CD33, and methods of using the antibodies or antigen-binding fragments thereof.

[0007] In certain embodiments, the CD33 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:18, SEQ ID NO:28, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:72, SEQ ID NO:81, or SEQ ID NO:88.

[0008] In certain embodiments, the anti-CD33 antibody, or antigen-binding fragment thereof, comprises a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:19, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:63, SEQ ID NO:73, SEQ ID NO:82, SEQ ID NO:89, or SEQ ID NO:92.

[0009] In certain embodiments, the anti-CD33 antibody, or antigen-binding fragment thereof, comprises: (a) an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:18, SEQ ID NO:28, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:72, SEQ ID NO:81, or SEQ ID NO:88. and (b) a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:19, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:63, SEQ ID NO:73, SEQ ID NO:82, SEQ ID NO:89, or SEQ ID NO:92.

[0010] In certain embodiments, the heavy and light chain variable regions of the anti-CD33 antibody, or antigen-binding fragment thereof, (a) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:8, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:9; (b) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:18, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:19; (c) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:28, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:29; (d) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:35, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:29; (e) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:43, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:44; (f) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:52, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:53; (g) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:62, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:63; (h) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 72, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 73; (i) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 81, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 81; (j) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:88, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:89; and (k) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:8, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:92.

[0011] In certain embodiments, the anti-CD33 antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:18, SEQ ID NO:28, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:72, SEQ ID NO:81, or SEQ ID NO:88.

[0012] In certain embodiments, the anti-CD33 antibody, or antigen-binding fragment thereof, comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:19, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:63, SEQ ID NO:73, SEQ ID NO:82, SEQ ID NO:89, or SEQ ID NO:92.

[0013] In certain embodiments, the CD33 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:18, SEQ ID NO:28, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:72, SEQ ID NO:81, and SEQ ID NO:88, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:19, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:63, SEQ ID NO:73, SEQ ID NO:82, SEQ ID NO:89, or SEQ ID NO:92.

[0014] In certain embodiments, the anti-CD33 antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region and a light chain variable region, (a) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9; (b) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 18, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 19; (c) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 28, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 29; (d) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 35, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 29; (e) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 43, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 44; (f) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 52, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 53; (g) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 62, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 63; (h) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 72, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 73; (i) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 81, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 82; (j) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 88, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 89; and (k) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:92.

[0015] In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof comprises a heavy chain constant region and / or a light chain constant region. In certain embodiments, the heavy chain constant region comprises an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 95. In certain embodiments, the heavy chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 95.

[0016] In certain embodiments, the light chain constant region comprises an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 96 or SEQ ID NO: 99. In certain embodiments, the light chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 96 or SEQ ID NO:99.

[0017] In certain embodiments, an anti-CD33 antibody, or antigen-binding fragment thereof, comprises (a) a heavy chain constant region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:95, and (b) a light chain constant region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:96 or SEQ ID NO:99.

[0018] In certain embodiments, the anti-CD33 antibody, or antigen-binding fragment thereof, (a) a heavy chain constant region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 95, and a light chain constant region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 96; or (b) a heavy chain constant region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:95, and a light chain constant region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:99.

[0019] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO:95.

[0020] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO:96 or SEQ ID NO:99.

[0021] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO:95, and a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO:96 or SEQ ID NO:99.

[0022] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 95, and a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 96; or (b) a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 95, and a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 99.

[0023] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a CDR1 domain, a CDR2 domain, and a CDR3 domain, and a light chain variable region comprising a CDR1 domain, a CDR2 domain, and a CDR3 domain, wherein the CDR3 domain of the heavy chain variable region and the light chain variable region comprises (a) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 4 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7 or a conservative modification thereof; (b) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17 or a conservative modification thereof; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27 or a conservative modification thereof; (d) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27 or a conservative modification thereof; (e) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42 or a conservative modification thereof; (f) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 51 or a conservative modification thereof; (g) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 58 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 61 or a conservative modification thereof; (h) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71 or a conservative modification thereof; (i) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 77 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 80 or a conservative modification thereof; and (j) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 87 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42 or a conservative modification thereof.

[0024] In certain embodiments, the heavy chain variable region and light chain variable region CDR2 domains of the antibody or antigen-binding fragment thereof are (a) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:3 and a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6 and a conservative modification thereof; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13 and conservative modifications thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16 and conservative modifications thereof; (c) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23 and a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26 and a conservative modification thereof; (d) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33 and a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26 and a conservative modification thereof; (e) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38 and a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41 and a conservative modification thereof; (f) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38 and conservative modifications thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 50 and conservative modifications thereof; (g) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57 and conservative modifications thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 60 and conservative modifications thereof; (h) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 67 and conservative modifications thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70 and conservative modifications thereof; (i) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57 and conservative modifications thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 79 and conservative modifications thereof; and (j) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86 and conservative modifications thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41 and conservative modifications thereof.

[0025] In certain embodiments, the CDR1 domains of the heavy and light chain variable regions of the antibody or antigen-binding fragment thereof comprise: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2 and a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5 and a conservative modification thereof; (b) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12 and a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15 and a conservative modification thereof; (c) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22 and a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25 and a conservative modification thereof; (d) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32 and a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25 and a conservative modification thereof; (e) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37 and conservative modifications thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 40 and conservative modifications thereof; (f) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 47 and a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 49 and a conservative modification thereof; (g) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 56 and a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 59 and a conservative modification thereof; (h) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 66 and conservative modifications thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69 and conservative modifications thereof; (i) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 76 and a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 78 and a conservative modification thereof; and (j) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 86 and conservative modifications thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5 and conservative modifications thereof.

[0026] In certain embodiments, one or more of the CDR sequences have up to about 5 amino acid substitutions. In certain embodiments, one or more of the CDR sequences have up to about 3 amino acid substitutions.

[0027] In certain embodiments, the anti-CD33 antibody, or antigen-binding fragment thereof, (a) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 3, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 4; (b) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14; (c) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24; (d) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; (e) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39; (f) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 47, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48; (g) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 56, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 58; (h) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 66, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 67, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68; (i) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 76, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 77; or (j) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 85, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 87.

[0028] In certain embodiments, the anti-CD33 antibody, or antigen-binding fragment thereof, (a) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7; (b) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17; (c) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27; (d) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 40, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42; (e) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 49, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 50, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 51; (f) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 59, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 60, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 61; (g) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; (h) a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 78, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 79, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 80; or (i) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:41, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:42.

[0029] In certain embodiments, the anti-CD33 antibody, or antigen-binding fragment thereof, (a) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:2, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:3, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:4, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7; (b) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17; (c) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27; (d) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27; (e) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 40, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42; (f) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 47, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 49, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 50, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 51; (g) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 56, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 58, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 59, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 60, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 61; (h) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 66, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 67, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 684, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; (i) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 76, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 77, and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 78, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 79, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 80; or (j) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 85, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 87, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42.

[0030] In certain embodiments, the antibody sequence is in the heavy-light variable chain orientation (V H -V L In certain embodiments, the antibody or antigen-binding fragment thereof comprises human variable region framework regions.

[0031] In certain embodiments, the antibody or antigen-binding fragment thereof is fully human or an antigen-binding fragment thereof. In certain embodiments, the antibody or antigen-binding fragment thereof is a chimeric antibody or an antigen-binding fragment thereof. In certain embodiments, the antibody or antigen-binding fragment thereof is a humanized antibody or an antigen-binding fragment thereof. In certain embodiments, the antigen-binding fragment of an antibody is a Fab, Fab', F(ab') 2 , a variable fragment (Fv), or a single chain variable fragment (scFv).

[0032] In certain embodiments, the antigen-binding fragment of an antibody or antigen-binding fragment thereof is an scFv.

[0033] Additionally, the presently disclosed subject matter provides antibodies, or antigen-binding fragments thereof, that cross-compete with any of the above-mentioned antibodies, or antigen-binding fragments thereof, for binding to CD33.

[0034] The presently disclosed subject matter further provides an antibody or antigen-binding fragment thereof that binds to the same epitope region on CD33 as any of the above-mentioned antibodies or antigen-binding fragments thereof.

[0035] The presently disclosed subject matter also provides an immunoconjugate comprising an antibody or antigen-binding fragment thereof disclosed herein linked to a therapeutic agent, hi certain embodiments, the therapeutic agent is a drug, a cytotoxin, or a radioisotope.

[0036] The presently disclosed subject matter further provides multispecific molecules comprising an antibody or antigen-binding fragment thereof disclosed herein linked to one or more functional moieties, in certain embodiments, the one or more functional moieties have a different binding specificity than the antibody or antigen-binding fragment thereof.

[0037] The presently disclosed subject matter further provides a composition comprising an antibody or antigen-binding fragment thereof disclosed herein, an immunoconjugate disclosed herein, or a multispecific molecule disclosed herein, hi certain embodiments, the composition is a pharmaceutical composition further comprising a pharma- ceutically acceptable carrier.

[0038] The subject matter disclosed herein provides a nucleic acid encoding an antibody or antigen-binding fragment thereof disclosed herein. Additionally, the subject matter disclosed herein provides a nucleic acid encoding a heavy chain variable region of an antibody or antigen-binding fragment thereof disclosed herein. In certain embodiments, the nucleic acid comprises a nucleotide sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the nucleotide sequence set forth in SEQ ID NO:10, SEQ ID NO:20, SEQ ID NO:30, SEQ ID NO:36, SEQ ID NO:45, SEQ ID NO:54, SEQ ID NO:64, SEQ ID NO:74, SEQ ID NO:83, SEQ ID NO:90, or SEQ ID NO:93. In certain embodiments, the nucleic acid comprises the nucleotide sequence set forth in SEQ ID NO:10, SEQ ID NO:20, SEQ ID NO:30, SEQ ID NO:36, SEQ ID NO:45, SEQ ID NO:54, SEQ ID NO:64, SEQ ID NO:74, SEQ ID NO:83, SEQ ID NO:90, or SEQ ID NO:93.

[0039] The presently disclosed subject matter further provides a nucleic acid encoding a light chain variable region of an antibody or antigen-binding fragment thereof disclosed herein. In certain embodiments, the nucleic acid comprises a nucleotide sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the nucleotide sequence set forth in SEQ ID NO:11, SEQ ID NO:21, SEQ ID NO:31, SEQ ID NO:46, SEQ ID NO:55, SEQ ID NO:65, SEQ ID NO:75, SEQ ID NO:84, SEQ ID NO:91, or SEQ ID NO:94. In certain embodiments, the nucleic acid comprises the nucleotide sequence set forth in SEQ ID NO:11, SEQ ID NO:21, SEQ ID NO:31, SEQ ID NO:46, SEQ ID NO:55, SEQ ID NO:65, SEQ ID NO:75, SEQ ID NO:84, SEQ ID NO:91, or SEQ ID NO:94.

[0040] The presently disclosed subject matter further provides vectors comprising such nucleic acid molecules, and host cells comprising such vectors.

[0041] The subject matter disclosed herein provides methods for detecting CD33 in a cell, tissue, or blood sample. In certain embodiments, the method includes contacting a cell, tissue, or blood sample with an antibody or antigen-binding fragment thereof disclosed herein, where the antibody or antigen-binding fragment thereof comprises a detectable label, and determining the amount of labeled antibody or antigen-binding fragment thereof bound to the cell, tissue, or blood sample by measuring the amount of detectable label associated with the cell, tissue, or blood sample, where the amount of bound antibody or antigen-binding fragment thereof indicates the amount of CD33 in the cell, tissue, or blood sample.

[0042] Furthermore, the subject matter disclosed herein provides various methods of using the antibodies and antigen-binding fragments thereof, immunoconjugates, multispecific molecules, or compositions disclosed herein. The subject matter disclosed herein provides a method of treating or ameliorating a disease or disorder associated with CD33 in a subject. In certain embodiments, the method comprises administering to the subject an antibody or antigen-binding fragment thereof, immunoconjugate, multispecific molecule, or composition disclosed herein. In certain embodiments, the disease or disorder expresses CD33. In certain embodiments, the disease or disorder is associated with overexpression of CD33. In certain embodiments, the disease or disorder is a tumor.

[0043] The subject matter disclosed herein also provides a method of reducing tumor burden in a subject. In certain embodiments, the method comprises administering to the subject an antibody or antigen-binding fragment thereof, immunoconjugate, multispecific molecule, or composition disclosed herein. In certain embodiments, the method reduces the number of tumor cells, reduces tumor size, and / or eradicates tumors in the subject.

[0044] Additionally, the subject matter disclosed herein also provides methods of treating and / or preventing a tumor in a subject, in certain embodiments, the method comprises administering to the subject an antibody or antigen-binding fragment thereof, immunoconjugate, multispecific molecule, or composition disclosed herein.

[0045] Additionally, the subject matter disclosed herein also provides methods of increasing or extending the survival time of a subject bearing a tumor. In certain embodiments, the methods comprise administering to the subject an antibody or antigen-binding fragment thereof, immunoconjugate, multispecific molecule, or composition disclosed herein. In certain embodiments, the methods reduce or eradicate the tumor burden in the subject.

[0046] In certain embodiments, the tumor is cancer. In certain embodiments, the tumor is a hematological cancer or a solid tissue cancer. In certain embodiments, the hematological cancer is selected from the group consisting of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), myeloproliferative neoplasms (MPN), and chronic myeloid neoplasms. In certain embodiments, the hematological cancer is acute myeloid leukemia (AML). In certain embodiments, the subject is a human.

[0047] The subject matter disclosed herein further provides a kit for treating or ameliorating a disease or disorder in a subject, for treating or ameliorating a disease or disorder in a subject, for reducing tumor burden in a subject, for treating and / or preventing a tumor in a subject, and / or for increasing or extending the survival time of a subject having a tumor, comprising an antibody or antigen-binding fragment thereof, immunoconjugate thereof, multispecific molecule thereof, or composition disclosed herein. In certain embodiments, the kit further comprises written instructions for using an antibody or antigen-binding fragment thereof, immunoconjugate thereof, multispecific molecule thereof, or composition disclosed herein for treating or ameliorating a disease or disorder in a subject, for treating or ameliorating a disease or disorder in a subject, for reducing tumor burden in a subject, for treating and / or preventing a tumor in a subject, and / or for increasing or extending the survival time of a subject having a tumor.

[0048] 4. Brief description of the drawings The following detailed description is given by way of example and is not intended to limit the invention to the particular embodiments described and may be understood in conjunction with the accompanying drawings. [Brief description of the drawings]

[0049] [Figure 1A] CD33 domain structure. A schematic diagram of full-length CD33 (CD33M) is shown, which consists of two Ig-like domains (IgV and IgC2) in the extracellular region, a single transmembrane segment, an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an ITIM-like motif in the cytoplasmic region. In the common CD33 variant (CD33m), the IgV domain is missing due to alternative splicing. [Figure 1B]CD33 domain structure is shown. CD33 gene structure with and without alternative splicing is shown. Removal of exon 2 results in loss of the IgV domain. Several antibodies that have progressed to the clinic in various formats (CAR, BiTE, radiotherapy) target the IgV domain. GO, gemtuzumab ozogamicin. [Diagram 2] Candidate antibodies binding to CD33 protein are shown. Binding of 10 selected clones tested by ELISA on mouse (moCD33) and human (huCD33) proteins. All 10 clone mAbs showed binding to human CD33 but not to mouse CD33. Anti-His, anti-CD33 and irrelevant proteins containing His were used as controls. [Diagram 3] Binding of candidate antibodies to recombinant CD33 protein is shown. Recombinant human, cynomolgus monkey and mouse CD33-ECD-Hi were captured by Ni plates and antibodies were added in triplicate at a concentration of 10 μg / mL. For detection, HRP-conjugated anti-human Fc secondary antibody was used. [Figure 4A] 1 shows the binding of exemplary monoclonal anti-CD33 antibodies disclosed herein to CD33 expressed on the cell surface. 2 shows the binding of monoclonal antibodies TDI-Y-006, TDI-Y-007, and 1J19 to CD33-overexpressing 3T3 cells. [Figure 4B] 1 shows the binding of exemplary monoclonal anti-CD33 antibodies disclosed herein to CD33 expressed on the cell surface. Binding of monoclonal antibodies TDI-Y-006, TDI-Y-007, and 1J19-U937, AML lines with endogenous CD33 expression, is shown. Binding was tested at increasing concentrations by flow cytometry. Human IgG1 (HuIgG1) isotype was included as a control. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0050] 5. Detailed Description of the Invention The presently disclosed subject matter provides anti-CD33 antibodies. Non-limiting embodiments of the disclosure are illustrated herein and by way of examples.

[0051] For clarity of disclosure, and not by way of limitation, this detailed description is divided into the following sections. 5.1. Definition, 5.2.CD33, 5.3. Anti-CD33 antibody, 5.4. Nucleic Acids Encoding Antibodies or Antigen-Binding Fragments 5.5. Pharmaceutical compositions and methods of treatment 5.6. Diagnostic and prognostic methods; 5.7. Kits, and 5.8. Illustrative Embodiments

[0052] 5.1.Definition In the following description, certain rules will be followed regarding the use of terms: In general, the terms used herein are intended to be interpreted consistently with the meaning of those terms as known to those skilled in the art.

[0053] As these terms are known in the art, "antibody" and "antibody(s)" refer to antigen-binding proteins of the immune system. The term "antibody" as referred to herein includes complete full-length antibodies having an antigen-binding region, and an "antigen-binding fragment" or any fragment thereof in which the "antigen-binding region" is retained, or a single chain thereof, e.g., a single-chain variable fragment (scFv). A naturally occurring "antibody" is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain comprises a heavy chain variable region (herein referred to as V H Each light chain is made up of a light chain variable region (abbreviated herein as V) and a heavy chain constant (CH) region. The heavy chain constant region is made up of three domains, CH1, CH2, and CH3. Each light chain is made up of a light chain variable region (abbreviated herein as V L (abbreviated as ) and light chain constant C L The light chain constant region consists of one domain, C L It consists of V H and V LThe regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDRs), interspersed with regions that are more conserved, called framework regions (FRs). H and V L is composed of three CDRs and four FRs arranged in the following order from amino terminus to carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of the antibody may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

[0054] The term "human antibody," as used herein, is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region also is derived from a human germline immunoglobulin sequence. Human antibodies of the presently disclosed subject matter may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).

[0055] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies constituting the population are identical and / or bind to the same epitope, except for possible variant antibodies, which may include, for example, naturally occurring mutations or arise during the production of the monoclonal antibody preparation, typically present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody obtained from a substantially homogeneous antibody population and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies used in accordance with the subject matter disclosed herein may be produced by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods as well as other exemplary methods for producing monoclonal antibodies described herein.

[0056] As used herein, the term "recombinant human antibody" includes all human antibodies prepared, expressed, generated, or isolated by recombinant means, such as (a) antibodies isolated from animals (e.g., mice) that are transgenic or transchromosomal for human immunoglobulin genes or hybridomas prepared therefrom (described further below), (b) antibodies isolated from host cells that have been transformed to express human antibodies, e.g., from transfectomas, (c) antibodies isolated from recombinant combinatorial human antibody libraries, and (d) antibodies prepared, expressed, generated, or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable regions in which the framework and CDR regions are derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies may be subjected to in vitro mutagenesis (or, when animals transgenic for human Ig sequences are used, in vivo somatic mutagenesis), thus allowing the V of the recombinant antibody to be modified. H Area and V L The amino acid sequence of the region is H Sequence and V L These are sequences that, while derived from and related to the sequence, may not naturally occur in the human antibody germline repertoire in vivo.

[0057] The term "humanized antibody" is intended to refer to antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. Additional framework region modifications may be made within the human framework sequences.

[0058] The term "chimeric antibody" is intended to refer to an antibody in which the variable region sequences are derived from one species and the constant region sequences are derived from another species, e.g., the variable region sequences are derived from a murine antibody and the constant region sequences are derived from a human antibody.

[0059] As used herein, an antibody that "specifically binds to CD33" has a concentration of about 1×10 -8M or less, about 5 x 10 -9 M or less, approximately 1×10 -9 M or less, about 5 x 10 -10 M or less, approximately 1×10 -10 M or less, about 5 x 10 -11 M or less, or about 1 x 10 -11 The dissociation constant (K D ), an antibody that binds to CD33 (e.g., human CD33, e.g., soluble human CD33).

[0060] An "antibody that competes for binding" or "antibody that cross-competes for binding" with a reference antibody for binding to an antigen, e.g., CD33, refers to an antibody that blocks the binding of the reference antibody to an antigen (e.g., CD33) by 50% or more in a competition assay, and conversely, the reference antibody blocks the binding of the antibody to an antigen (e.g., CD33) by 50% or more in a competition assay. Exemplary competition assays are described in "Antibodies", Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harbor, NY).

[0061] As used herein, "isotype" refers to the antibody class (e.g., IgM or IgG1) that is encoded by heavy chain constant region genes.

[0062] The phrases "an antibody that recognizes an antigen" and "an antibody specific for an antigen" may be used interchangeably herein with the term "an antibody that specifically binds to an antigen (eg, a CD33 polypeptide)."

[0063] As used herein, the term "antigen-binding fragment" or "antigen-binding region" of an antibody refers to a region or fragment of an antibody that binds to an antigen and confers antigen specificity to the antibody, and includes fragments of antigen-binding proteins, e.g., antibodies, including one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., a CD33 polypeptide). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of antigen-binding fragments encompassed by the term "antibody fragment" of an antibody include V L , VH , C L and a Fab fragment, which is a monovalent fragment consisting of a CH1 domain; and a F(ab) fragment, which is a bivalent fragment containing two Fab fragments linked by a disulfide bridge at the hinge region. 2 Fragment, V H and an Fd fragment consisting of the CH1 domain, a V L and V H Fv fragment consisting of domains, V H These include dAb fragments consisting of domains (Ward et al., Nature 1989;341:544-546), as well as isolated complementarity determining regions (CDRs).

[0064] In addition, the two domains V of the Fv fragment L and V H are encoded by separate genes, but these are referred to as V L and V H The antibody fragments can be joined using recombinant methods by synthetic linkers that allow the domains to be produced as a single protein chain that pairs to form a monovalent molecule. These are known as single-chain Fvs (scFvs), see, e.g., Bird et al., Science (1988); 242:423-426, and Huston et al., Proc Natl Acad Sci (1998); 85:5879-5883. These antibody fragments are obtained using conventional techniques known to those of skill in the art, and the fragments are screened for utility in the same manner as intact antibodies.

[0065] An "antibody" or "antigen binding protein" is one that has been identified, separated and / or recovered from a component of its natural environment. A "synthetic antibody" or "recombinant antibody" is generally produced using recombinant techniques, or using peptide synthesis techniques known to those of skill in the art.

[0066] As used herein, the term "single chain variable fragment" or "scFv" refers to a V H :V LHeavy chains (V) of immunoglobulins (e.g., mouse or human) covalently linked to form heterodimers H ) and light chain (V L ) is a fusion protein of the variable regions of the heavy chain (V H ) and light chain (V L ) are either directly connected or connected by a peptide-encoding linker (e.g., 10, 15, 20, 25 amino acids), H N-terminus of V L or V H The C-terminus of V L The linker is usually rich in glycine for flexibility and rich in serine or threonine for solubility. The linker may link the heavy and light chain variable regions of the extracellular antigen-binding domain.

[0067] Non-limiting examples of linkers are disclosed in Shen et al., Anal Chem (2008); 80(6): 1910-1917 and WO2014 / 087010, the contents of which are incorporated herein by reference in their entirety. In certain embodiments, the linker is a G4S linker. In certain embodiments, the linker comprises or consists of the amino acid sequence set forth in SEQ ID NO: 104, which is provided below. GGGGSGGGGSGGGSGGGGS [SEQ ID NO: 104]

[0068] In certain embodiments, the linker comprises or consists of the amino acid sequence set forth in SEQ ID NO: 105, which is provided below. GGGGSGGGGSGGGGS [SEQ ID NO: 105]

[0069] In certain embodiments, the linker comprises or consists of the amino acid sequence set forth in SEQ ID NO: 106, which is provided below. GGGGSGGGGSGGGGSGGGSGGGGS [SEQ ID NO: 106]

[0070] In certain embodiments, the linker comprises or consists of the amino acid sequence set forth in SEQ ID NO: 107, which is provided below. GGGGSGGGGSGGGGSGGGGSGGGSGGGGS [SEQ ID NO: 107]

[0071] In certain embodiments, the linker comprises or consists of the amino acid sequence set forth in SEQ ID NO: 108, which is provided below. GGGGS [SEQ ID NO: 108]

[0072] In certain embodiments, the linker comprises or consists of the amino acid sequence set forth in SEQ ID NO: 109, which is provided below. GGGGSGGGGS [SEQ ID NO: 109]

[0073] Despite the removal of the constant region and the introduction of the linker, the scFv protein retains the specificity of the original immunoglobulin. Single-chain Fv polypeptide antibodies are synthesized by the VFv method, as described by Huston, et al. (Proc. Nat. Acad. Sci. USA, 1988; 85:5879-5883). H and V LThe polypeptide can be expressed from a nucleic acid containing a sequence encoding the polypeptide. See also U.S. Patent Nos. 5,091,513, 5,132,405, and 4,956,778, and U.S. Patent Publication Nos. 2005 / 0196754 and 2005 / 0196754. Antagonistic scFvs with inhibitory activity have been described (e.g., Zhao et al., Hyrbidoma (Larchmt) 2008;27(6):455-51; Peter et al., J Cachexia Sarcopenia Muscle 2012 August 12; Shieh et al., J Imunol 2009;183(4):2277-85; Giomarelli et al., Thromb Haemost 2007;97(6):955-63; Fife et al., J Clin Invst 2006;116(8):2252-61; Brocks et al., Immunotechnology 1997;3(3):173-84; Moosmayer et al., Ther Immunol 1995;2(10:31-40). Agonistic scFvs with stimulatory activity have been described (see, e.g., Peter et al., J Bioi Chern 2003;25278(38):36740-7; Xie et al., Nat Biotech 1997;15(8):768-71; Ledbetter et al., Crit Rev Immunol 1997;17(5-6):427-55; Ho et al., BioChim Biophys Acta 2003;1638(3):257-66).

[0074] As used herein, "F(ab)" refers to the fragment of an antibody structure that binds an antigen but is monovalent and does not have the Fc portion; for example, an antibody digested with the enzyme papain produces two F(ab) fragments and an Fc fragment (the heavy (H) chain constant region, the Fc region that does not bind antigen).

[0075] As used herein, "F(ab') 2"F(ab')" refers to an antibody fragment produced by pepsin digestion of a whole IgG antibody, which fragment has two antigen-binding (ab') (bivalent) regions, each (ab') region containing two separate amino acid chains, a portion of a heavy chain and a light (L) chain, linked by S-S bonds to bind antigen, and the remaining portions of the heavy chains linked together. 2 The Fab' fragment can be separated into two individual Fab' fragments.

[0076] As used herein, the term "vector" refers to any genetic element, such as a plasmid, phage, transposon, cosmid, chromosome, virus, virion, etc., that is capable of replicating and transferring genetic sequences into a cell when associated with the appropriate control elements. Thus, the term includes cloning and expression vehicles, as well as viral vectors and plasmid vectors.

[0077] "CDR" is defined as the complementarity determining region amino acid sequences of an antibody that are the hypervariable regions of the immunoglobulin heavy and light chains. See, for example, Kabat et al., Sequences of Proteins of Immunological Interest, 4th USDepartment of Health and Human Services, National Institutes of Health (1987), or the IMGT numbering system (Lefranc, The Immunologist (1999); 7:132-136; Lefranc et al., Dev. Comp. Immunol. (2003); 27:55-77). As used herein, the term "hypervariable region" or "HVR" refers to each of the regions of an antibody variable domain that are hypervariable in sequence ("complementarity determining region" or "CDR") and / or form structurally defined loops ("hypervariable loops") and / or contain antigen contact residues ("antigen contacts"). Generally, an antibody contains three heavy and three light chain CDRs or CDR regions in the variable region. CDRs provide the majority of contact residues for the binding of an antibody to an antigen or epitope region. In certain embodiments, CDRs are identified according to the IMGT system. In certain embodiments, CDRs are identified using the IMGT numbering system, accessible at http: / / www.imgt.org / IMGT_vquest / input.

[0078] The term "isolated" denotes the degree of separation from the original source or surroundings.

[0079] An "isolated antibody" is one that has been separated from a component of its natural environment. In certain embodiments, the antibody is purified to greater than 95% or 99% purity, for example, as determined by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse phase HPLC). For a review of methods for assessing antibody purity, see, for example, Flatman et al., J. Chromatogr (2007); B 848: 79-87.

[0080] "Isolated nucleic acid" refers to a nucleic acid molecule that has been separated from a component of its natural environment. Isolated nucleic acid includes a nucleic acid molecule contained in a cell that ordinarily contains the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0081] "Isolated nucleic acid encoding an antibody" (including reference to a specific antibody, e.g., an anti-KLB antibody) refers to one or more nucleic acid molecules encoding the antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector, separate vectors, and such nucleic acid molecule(s) present in one or more locations in a host cell.

[0082] The term "vector," as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors as self-replicating nucleic acid structures as well as vectors that are integrated into the genome of a host cell into which they are introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors."

[0083] An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules, including, but not limited to, a cytotoxic agent.

[0084] As used herein, the term "derivative" refers to a compound that is derived from some other compound and maintains its general structure. For example, but not by way of limitation, trichloromethane (chloroform) is a derivative of methane.

[0085] An "effective amount" (or "therapeutically effective amount") is an amount sufficient to produce a beneficial or desired clinical result upon treatment. An effective amount may be administered to a subject in one or more doses. In terms of treatment, an effective amount is an amount sufficient to palliate, ameliorate, stabilize, reverse or slow the progression of a disease, or otherwise reduce the pathological consequences of a disease. An effective amount is generally determined by a physician on a case-by-case basis and is within the skill of one of ordinary skill in the art. Several factors are typically considered in determining the appropriate dosage to achieve an effective amount. These factors include the age, sex, and weight of the subject, the condition being treated, the severity of the condition, and the form and effective concentration of the cells to be administered.

[0086] An "individual" or "subject" herein is a vertebrate, e.g., a human or a non-human animal, e.g., a mammal. Mammals include, but are not limited to, humans, primates, farm animals, sport animals, rodents, and pets. Non-limiting examples of non-human animal subjects include rodents, such as mice, rats, and hamsters, guinea pigs, rabbits, dogs, cats, sheep, pigs, goats, cows, horses, and non-human primates, such as apes and monkeys.

[0087] As used herein, "treatment" (and grammatical variations thereof, e.g., "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, improving or ameliorating the disease state, and remission or improved prognosis. In certain embodiments, the antibodies of the subject matter disclosed herein are used to delay the onset of disease or to slow the progression of a disease, e.g., a tumor, e.g., a tumor associated with CD33.

[0088] The terms "comprises" and "comprising" are intended to have the broad meaning ascribed to them in U.S. patent law and can mean "includes," "including," etc.

[0089] As used herein, the term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within 3 or more than 3 standard deviations, as is customary in the art. Alternatively, "about" can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and even more preferably up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, more preferably within 2-fold of a value.

[0090] As described herein, any concentration range, percentage range, ratio range, or integer range should be understood to include any integer value within the recited range, and, where appropriate, fractions thereof (such as tenths and hundredths of integers), unless otherwise indicated.

[0091] Other aspects of the presently disclosed subject matter are described in the disclosure that follows and are within the scope of the presently disclosed subject matter.

[0092] 5.2.CD33 CD33 is a single-pass transmembrane molecule and a member of the sialic acid-binding immunoglobulin (Ig)-like lectin (Siglec) family. CD33 consists of two extracellular domains with an immunoglobulin-like fold, IgV and IgC2 (see FIG. 1A). CD33 has three isoforms produced by alternative splicing, with isoform 3 lacking the IgV domain (Ehninger et al., Blood Cancer J 4, e218 (2014); Sanford et al., Leuk Lymphoma 57, 1965-1968 (2016); and Haubner et al., Leukemia 33, 64-74 (2019)). Recent studies have shown that approximately 50% of AML patients have a CD33 single nucleotide polymorphism (SNP) (rs12459419C>T) that results in the expression of an alternatively spliced ​​CD33 isoform lacking exon 2, resulting in the elimination of the IgV domain (Bakker et al., Cancer Res 64, 8443-8450 (2004)). In these patients, the CD33-targeting antibody-drug conjugate (ADC), gemtuzumab ozogamicin (GO), had no effect and increased the risk of relapse, likely due to the inability of this ADC to kill AML cells expressing this IgV-deficient CD33 isoform, a problem encountered by all currently clinically available CD33-targeting products, given their epitopes in the IgV domain (see Figure 1B) (see Perna et al., Cancer Cell 32, 506-519 e505 (2017)).

[0093] In certain embodiments, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein bind to human CD33. In certain embodiments, the human CD33 comprises or consists of an amino acid sequence having UniProt Reference Number: P20138-1 (SEQ ID NO: 1), or a fragment thereof. SEQ ID NO: 1 is provided below. In certain embodiments, the human CD33 comprises an extracellular domain, a transmembrane domain, and a cytoplasmic domain. In certain embodiments, the extracellular domain comprises or consists of amino acids 18-259 of SEQ ID NO: 1. In certain embodiments, the transmembrane domain comprises or consists of amino acids 260-282 of SEQ ID NO: 1. In certain embodiments, the cytoplasmic domain comprises or consists of amino acids 283-364 of SEQ ID NO: 1. [ka]

[0094] In certain embodiments, CD33 comprises or consists of an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% identical to the amino acid sequence set forth in SEQ ID NO:1, or a fragment thereof.

[0095] In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof binds to a portion of human CD33. In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof binds to the extracellular domain of CD33. In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof binds to amino acids 18-259 of SEQ ID NO:1.

[0096] 5.3. Anti-CD33 antibody The antibodies of the presently disclosed subject matter are characterized by a particular functional feature or property of the antibody, for example, the antibody specifically binds to CD33 (e.g., binds to human CD33).

[0097] In certain embodiments, the antibodies or antigen-binding fragments disclosed herein have a binding affinity to CD33 (e.g., human CD33) of, for example, 1×10 -8 M or less, for example, about 1×10 -8 M or less, about 5 x 10 -9 M or less, approximately 1×10 -9 M or less, about 5 x 10 -10 M or less, approximately 1×10 -10 M or less, or about 1 x 10 -11 The dissociation constant (K D In certain embodiments, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein bind at about 5×10 -9 The dissociation constant (K D In certain embodiments, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein bind to CD33 (e.g., human CD33, e.g., soluble human CD33) at about 5×10 -9 Dissociation constant of M (K D In certain embodiments, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein bind to CD33 (e.g., human CD33, e.g., soluble human CD33) at about 1×10 -9 Dissociation constant of M (K D In certain embodiments, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein bind to CD33 (e.g., human CD33, e.g., soluble human CD33) at about 1×10 -9 M ~ approx. 5×10 -9 Dissociation constant of M (K D In certain embodiments, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein bind to CD33 (e.g., human CD33, e.g., soluble human CD33) at about 1×10 -9 M ~ approx. 2×10 -9 Dissociation constant of M (K D In certain embodiments, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein bind to CD33 (e.g., human CD33, e.g., soluble human CD33) at about 5×10 -9 Dissociation constant of M (K DIn certain embodiments, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein bind to CD33 (e.g., human CD33, e.g., soluble human CD33) at about 1×10 -9 Dissociation constant of M (K D ) binds to CD33 (e.g., human CD33, e.g., soluble human CD33).

[0098] In certain embodiments, the antibodies or antigen-binding fragments disclosed herein have a half maximal effective concentration (EC) of about 1 nM to about 50 nM, about 5 nM to about 50 nM, about 10 nM to about 50 nM, about 20 nM to about 50 nM, about 30 nM to about 50 nM, about 40 nM to about 50 nM, or greater than about 50 nM. 50 In certain embodiments, the antibodies or antigen-binding fragments disclosed herein bind to cells expressing CD33 (e.g., AML cells expressing CD33) with an EC value of about 1 nM to about 5 nM. 50 In certain embodiments, the antibodies or antigen-binding fragments disclosed herein bind to cells expressing CD33 (e.g., AML cells expressing CD33) with an EC value of about 2 nM. 50 In certain embodiments, the antibodies or antigen-binding fragments disclosed herein bind to cells expressing CD33 (e.g., AML cells expressing CD33) with an EC value of about 2.16 nM. 50 In certain embodiments, the antibodies or antigen-binding fragments disclosed herein bind to cells expressing CD33 (e.g., AML cells expressing CD33) with an EC value of about 5 nM to about 10 nM. 50 In certain embodiments, the antibodies or antigen-binding fragments disclosed herein bind to cells expressing CD33 (e.g., AML cells expressing CD33) with an EC value of about 10 nM. 50 In certain embodiments, the antibodies or antigen-binding fragments disclosed herein bind to cells expressing CD33 (e.g., AML cells expressing CD33) with an EC value of about 8.5 nM. 50 In certain embodiments, the antibodies or antigen-binding fragments disclosed herein bind to cells expressing CD33 (e.g., AML cells expressing CD33) with an EC value of about 40 nM to about 50 nM.50 In certain embodiments, the antibodies or antigen-binding fragments disclosed herein bind to cells expressing CD33 (e.g., AML cells expressing CD33) with an EC value of about 45 nM. 50 In certain embodiments, the antibodies or antigen-binding fragments disclosed herein bind to cells expressing CD33 (e.g., AML cells expressing CD33) with an EC value of about 45 nM. 50 The antibody binds to cells expressing CD33 (e.g., AML cells expressing CD33) at low levels.

[0099] The heavy and light chains of the antibodies or antigen-binding fragments disclosed herein can be full length (e.g., an antibody can include at least one (e.g., one or two) complete heavy chains and at least one (e.g., one or two) complete light chains) or can be antigen-binding fragments (Fab, F(ab')). 2 , Fv or single chain Fv fragment ("scFv"). In certain embodiments, the antibody heavy chain constant region is selected from, for example, IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE, particularly, for example, IgG1, IgG2, IgG3, and IgG4. In certain embodiments, the immunoglobulin isotype is IgG1 (e.g., human IgG1). The choice of antibody isotype may depend on the immune effector function that the antibody is designed to elicit. In certain embodiments, the antibody light chain constant region is selected from, for example, kappa or lambda, particularly kappa.

[0100] In constructing recombinant immunoglobulins, the appropriate amino acid sequences for the constant regions of various immunoglobulin isotypes and methods for producing a wide range of antibodies are known to those of skill in the art.

[0101] 5.3.1. Single-chain variable fragments (scFv) In certain embodiments, the subject matter disclosed herein includes antibodies or antigen-binding fragments thereof in which the scFv sequence is fused to one or more constant domains to form an antibody with the Fc region of a human immunoglobulin, producing a bivalent protein and increasing the overall affinity and stability of the antibody. In addition, the Fc portion allows other molecules, including but not limited to, fluorochromes, cytotoxins, radioisotopes, etc., to be directly conjugated to the antibody for use, for example, in antigen quantification studies, for affinity measurements, for targeted delivery of therapeutics, to test Fc-mediated cytotoxicity using immune effector cells, and many other applications.

[0102] The results presented herein highlight the specificity, sensitivity and utility of the antibodies or antigen-binding fragments disclosed herein that target CD33 polypeptides (eg, human CD33 polypeptides).

[0103] In certain embodiments, the anti-CD33 scFv is an scFv-Fc fusion protein or a VFv selected from Table 1. H and V L In certain embodiments, the anti-CD33 scFv is a full-length human IgG having a V domain or CDR. H An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO:8 is set forth in SEQ ID NO:10. In certain embodiments, the anti-CD33 scFv comprises a VF comprising the amino acid sequence set forth in SEQ ID NO:9. L An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO:9 is set forth in SEQ ID NO:11. SEQ ID NOs:8-11 are provided in Table 1. In certain embodiments, the scFv is designated "3-P14."

[0104] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:8. H and V comprising the amino acid sequence set forth in SEQ ID NO:9. L Includes.

[0105] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:2 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:3 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:4 or a conservative modification thereof. H SEQ ID NOs: 2-4 are provided in Table 1.

[0106] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7 or a conservative modification thereof. L SEQ ID NOs: 4-6 are provided in Table 1.

[0107] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:2 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:3 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:4 or a conservative modification thereof. H and a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7 or a conservative modification thereof. L Includes.

[0108] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:2, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:3, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:4. H and CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7. L Includes.

[0109] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:8. H and V comprising the amino acid sequence set forth in SEQ ID NO:9. L In certain embodiments, V H and V L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 105.

[0110] In certain embodiments, the variable region is a heavy chain variable region (V H ) are located at the N-terminus. In certain embodiments, the variable regions are arranged from the N-terminus to the C-terminus: H -V L In certain embodiments, the light chain variable region (V L ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: L -V H . [Table 1]

[0111] In certain embodiments, the anti-CD33 scFv is an scFv-Fc fusion protein or a VFv selected from Table 2. H and V L In certain embodiments, the anti-CD33 scFv is a full-length human IgG having a V domain or CDR. H An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 18 is set forth in SEQ ID NO: 20. In certain embodiments, the anti-CD33 scFv comprises a VFv comprising the amino acid sequence set forth in SEQ ID NO: 19. L An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 19 is set forth in SEQ ID NO: 21. In certain embodiments, the anti-CD33 scFv comprises a VFv comprising the amino acid sequence set forth in SEQ ID NO: 18. H and V comprising the amino acid sequence set forth in SEQ ID NO:19.L SEQ ID NOs: 18-21 are provided in Table 2. In one particular embodiment, the scFv is designated "4-B2."

[0112] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14 or a conservative modification thereof. H SEQ ID NOs: 12-14 are provided in Table 2.

[0113] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17 or a conservative modification thereof. L SEQ ID NOs: 15-17 are provided in Table 2.

[0114] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14 or a conservative modification thereof. H and a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17 or a conservative modification thereof. L Includes.

[0115] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14. HC, and CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17. L Includes.

[0116] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO: 18. H and V comprising the amino acid sequence set forth in SEQ ID NO:19. L In certain embodiments, V H and V L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 105.

[0117] In certain embodiments, the heavy chain variable region (V H ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: H -V L In certain embodiments, the light chain variable region (V L ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: L -V H . [Table 2]

[0118] In certain embodiments, the anti-CD33 scFv is an scFv-Fc fusion protein or a VFv selected from Table 3. H and V L In certain embodiments, the anti-CD33 scFv is a full-length human IgG having a V domain or CDR. H An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO:28 is set forth in SEQ ID NO:30. In certain embodiments, the anti-CD33 scFv comprises a VFv comprising the amino acid sequence set forth in SEQ ID NO:29. LAn exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 29 is set forth in SEQ ID NO: 31. SEQ ID NOs: 28-31 are provided in Table 3. In certain embodiments, the scFv is designated "1-J19."

[0119] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:28. H and V comprising the amino acid sequence set forth in SEQ ID NO:29. L Includes.

[0120] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24 or a conservative modification thereof. H SEQ ID NOs:22-24 are provided in Table 3.

[0121] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27 or a conservative modification thereof. L SEQ ID NOs:25-27 are provided in Table 3.

[0122] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24 or a conservative modification thereof. H and a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:25 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:26 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:27 or a conservative modification thereof. L Includes.

[0123] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24. H and CDR1 comprising the amino acid sequence set forth in SEQ ID NO:25, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:26, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:27. L Includes.

[0124] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:28. H and V comprising the amino acid sequence set forth in SEQ ID NO:29. L In certain embodiments, V H and V L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 105.

[0125] In certain embodiments, the heavy chain variable region (V H ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: H -V L In certain embodiments, the light chain variable region (V L ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: L -V H [Table 3]

[0126] In certain embodiments, the anti-CD33 scFv is an scFv-Fc fusion protein or a VFv selected from Table 4. H and V L In certain embodiments, the anti-CD33 scFv is a full-length human IgG having a V domain or CDR.H An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 35 is set forth in SEQ ID NO: 36. In certain embodiments, the anti-CD33 scFv comprises a VFv comprising the amino acid sequence set forth in SEQ ID NO: 29. L An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO:29 is set forth in SEQ ID NO:31. SEQ ID NOs:29, 31, 35, and 36 are provided in Table 4. In certain embodiments, the scFv is designated "1-J19-2"

[0127] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:35. H and V comprising the amino acid sequence set forth in SEQ ID NO:29. L SEQ ID NOs: 35 and 29 are provided in Table 4.

[0128] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof. H SEQ ID NOs:32-34 are provided in Table 4.

[0129] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27 or a conservative modification thereof. L SEQ ID NOs:25-27 are provided in Table 4.

[0130] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof. Hand a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:25 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:26 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:27 or a conservative modification thereof. L Includes.

[0131] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34. H and CDR1 comprising the amino acid sequence set forth in SEQ ID NO:25, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:26, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:27. L Includes.

[0132] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:35. H and V comprising the amino acid sequence set forth in SEQ ID NO:29. L In certain embodiments, V H and V L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 105.

[0133] In certain embodiments, the heavy chain variable region (V H ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: H -V L In certain embodiments, the light chain variable region (V L ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: L -V H . [Table 4]

[0134] In certain embodiments, the anti-CD33 scFv is an scFv-Fc fusion protein or a VFv selected from Table 5. H and V L In certain embodiments, the anti-CD33 scFv is a full-length human IgG having a V domain or CDR. H An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 43 is set forth in SEQ ID NO: 45. In certain embodiments, the anti-CD33 scFv comprises a VFv comprising the amino acid sequence set forth in SEQ ID NO: 44. L An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 44 is set forth in SEQ ID NO: 46. SEQ ID NOs: 43-46 are provided in Table 5. In certain embodiments, the scFv is designated "1-P13."

[0135] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:43. H and V comprising the amino acid sequence set forth in SEQ ID NO:44. L Includes.

[0136] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39 or a conservative modification thereof. H SEQ ID NOs:37-39 are provided in Table 5.

[0137] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 40 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42 or a conservative modification thereof. L SEQ ID NOs: 40-42 are provided in Table 5.

[0138] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39 or a conservative modification thereof. H and a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 40 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42 or a conservative modification thereof. L Includes.

[0139] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39. H and CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 40, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42. L Includes.

[0140] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:43. H and V comprising the amino acid sequence set forth in SEQ ID NO:44. L In certain embodiments, V H and V L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 105.

[0141] In certain embodiments, the heavy chain variable region (V H ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: H -V L In certain embodiments, the light chain variable region (V L) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: L -V H . [Table 5]

[0142] In certain embodiments, the anti-DLL scFv is an scFv-Fc fusion protein or a VFv selected from Table 6. H and V L In certain embodiments, the anti-CD33 scFv is a full-length human IgG having a V domain or CDR. H An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO:52 is set forth in SEQ ID NO:54. In certain embodiments, the anti-CD33 scFv comprises a VFv comprising the amino acid sequence set forth in SEQ ID NO:53. L An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO:53 is set forth in SEQ ID NO:55. SEQ ID NOs:52-55 are provided in Table 6. In certain embodiments, the scFv is designated "1-P23."

[0143] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:52. H and V comprising the amino acid sequence set forth in SEQ ID NO:53. L Includes.

[0144] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 47 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48 or a conservative modification thereof. H SEQ ID NOs: 47, 38, and 48 are provided in Table 6.

[0145] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 49 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 50 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 51 or a conservative modification thereof. L SEQ ID NOs: 49-51 are provided in Table 6.

[0146] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 47 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48 or a conservative modification thereof. H and a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 49 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 50 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 51 or a conservative modification thereof. L Includes.

[0147] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:47, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:38, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:48. H and CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 49, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 50, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 51. L Includes.

[0148] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:52. H and V comprising the amino acid sequence set forth in SEQ ID NO:53. L In certain embodiments, V H and V L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 105.

[0149] In certain embodiments, the heavy chain variable region (V H ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: H -V L In certain embodiments, the light chain variable region (V L ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: L -V H [Table 6]

[0150] In certain embodiments, the anti-CD33 scFv is an scFv-Fc fusion protein or a VFv selected from Table 7. H and V L In certain embodiments, the anti-CD33 scFv is a full-length human IgG having a V domain or CDR. H An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO:62 is set forth in SEQ ID NO:64. In certain embodiments, the anti-CD33 scFv comprises a VFv comprising the amino acid sequence set forth in SEQ ID NO:63. L An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 63 is set forth in SEQ ID NO: 65. SEQ ID NOs: 62-65 are provided in Table 7. In certain embodiments, the scFv is designated "1-A20."

[0151] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:62. H and V comprising the amino acid sequence set forth in SEQ ID NO:63. L Includes.

[0152] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 56 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 58 or a conservative modification thereof. H SEQ ID NOs:56-58 are provided in Table 7.

[0153] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:59 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:60 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:61 or a conservative modification thereof. L SEQ ID NOs: 59-61 are provided in Table 7.

[0154] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 56 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 58 or a conservative modification thereof. H and a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:59 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:60 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:61 or a conservative modification thereof. L Includes.

[0155] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:56, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:57, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:58. H and CDR1 comprising the amino acid sequence set forth in SEQ ID NO:59, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:60, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:61. L Includes.

[0156] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:62. H and V comprising the amino acid sequence set forth in SEQ ID NO:63. L In certain embodiments, V H and V L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 105.

[0157] In certain embodiments, the heavy chain variable region (V H ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: H -V L In certain embodiments, the light chain variable region (V L ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: L -V H . [Table 7]

[0158] In certain embodiments, the anti-CD33 scFv is an scFv-Fc fusion protein or a VFv selected from Table 8. H and V L In certain embodiments, the anti-CD33 scFv is a full-length human IgG having a V domain or CDR. H An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 72 is set forth in SEQ ID NO: 74. In certain embodiments, the anti-CD33 scFv comprises a VFv comprising the amino acid sequence set forth in SEQ ID NO: 73. L An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 73 is set forth in SEQ ID NO: 75. SEQ ID NOs: 72-75 are provided in Table 8. In certain embodiments, the scFv is designated "2-N3."

[0159] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:72. H and V comprising the amino acid sequence set forth in SEQ ID NO:73. L Includes.

[0160] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 66 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 67 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68 or a conservative modification thereof. H SEQ ID NOs:66-68 are provided in Table 8.

[0161] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71 or a conservative modification thereof. L SEQ ID NOs: 69-71 are provided in Table 8.

[0162] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 66 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 67 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68 or a conservative modification thereof. H and a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:69 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:70 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:71 or a conservative modification thereof. L Includes.

[0163] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 66, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 67, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68. Hand CDR1 comprising the amino acid sequence set forth in SEQ ID NO:69, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:70, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:71. L Includes.

[0164] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:72. H and V comprising the amino acid sequence set forth in SEQ ID NO:73. L In certain embodiments, V H and V L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 105.

[0165] In certain embodiments, the heavy chain variable region (V H ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: H -V L In certain embodiments, the light chain variable region (V L ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: L -V H . [Table 8]

[0166] In certain embodiments, the anti-CD33 scFv is an scFv-Fc fusion protein or a VFv selected from Table 9. H and V L In certain embodiments, the anti-CD33 scFv is a full-length human IgG having a V domain or CDR. H An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 81 is set forth in SEQ ID NO: 83. In certain embodiments, the anti-CD33 scFv comprises a VFv comprising the amino acid sequence set forth in SEQ ID NO: 82. LAn exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 82 is set forth in SEQ ID NO: 84. SEQ ID NOs: 81-84 are provided in Table 9. In certain embodiments, the scFv is designated "1-H19."

[0167] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:81. H and V comprising the amino acid sequence set forth in SEQ ID NO:82. L Includes.

[0168] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 76 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 77 or a conservative modification thereof. H SEQ ID NOs: 76, 57, and 77 are provided in Table 9.

[0169] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 78 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 79 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 80 or a conservative modification thereof. L SEQ ID NOs:78-80 are provided in Table 9.

[0170] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 76 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 77 or a conservative modification thereof. H and CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 78 or a conservative modification thereof, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 79 or a conservative modification thereof, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 80 or a conservative modification thereof. L Includes.

[0171] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 76, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 77. H and CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 78, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 79, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 80. L Includes.

[0172] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:81. H and V comprising the amino acid sequence set forth in SEQ ID NO:82. L In certain embodiments, V H and V L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 105.

[0173] In certain embodiments, the heavy chain variable region (V H ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: H -V L In certain embodiments, the light chain variable region (V L ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: L -V H . [Table 9]

[0174] In certain embodiments, the anti-CD33 scFv is an scFv-Fc fusion protein or a VFv selected from Table 10. H and V LIn certain embodiments, the anti-CD33 scFv is a full-length human IgG having a V domain or CDR. H An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 88 is set forth in SEQ ID NO: 90. In certain embodiments, the anti-CD33 scFv comprises a VFv comprising the amino acid sequence set forth in SEQ ID NO: 89. L An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 89 is set forth in SEQ ID NO: 91. SEQ ID NOs: 88-91 are provided in Table 10. In certain embodiments, the scFv is designated "2-F18".

[0175] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:88. H and V comprising the amino acid sequence set forth in SEQ ID NO:89. L Includes.

[0176] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 85 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 87 or a conservative modification thereof. H SEQ ID NOs:85-87 are provided in Table 10.

[0177] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:41 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:42 or a conservative modification thereof. L SEQ ID NOs: 5, 41, and 42 are provided in Table 10.

[0178] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 85 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 87 or a conservative modification thereof. H and a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:41 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:42 or a conservative modification thereof. L Includes.

[0179] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 85, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 87. H and CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:41, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:42. L Includes.

[0180] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:88. H and V comprising the amino acid sequence set forth in SEQ ID NO:89. L In certain embodiments, V H and V L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 105.

[0181] In certain embodiments, the heavy chain variable region (V H ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: H -V L In certain embodiments, the light chain variable region (V L) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: L -V H . [Table 10]

[0182] In certain embodiments, the anti-CD33 scFv is an scFv-Fc fusion protein or a VFv selected from Table 11. H and V L In certain embodiments, the anti-CD33 scFv is a full-length human IgG having a V domain or CDR. H An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO:8 is set forth in SEQ ID NO:93. In certain embodiments, the anti-CD33 scFv comprises a VFv comprising the amino acid sequence set forth in SEQ ID NO:92. L An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO:92 is set forth in SEQ ID NO:94. SEQ ID NOs:8, 92, 93, and 94 are provided in Table 11. In certain embodiments, the scFv is designated "4-P3."

[0183] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:8. H and V comprising the amino acid sequence set forth in SEQ ID NO:92. L Includes.

[0184] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:2 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:3 or a conservative modification thereof, and an amino acid sequence set forth in SEQ ID NO:4 or a conservative modification thereof. H V containing CDR3 H SEQ ID NOs: 2-4 are provided in Table 11.

[0185] In certain embodiments, the anti-DDL3 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7 or a conservative modification thereof. L SEQ ID NOs: 5-7 are provided in Table 11.

[0186] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:2 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:3 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:4 or a conservative modification thereof. H and a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7 or a conservative modification thereof. L Includes.

[0187] In certain embodiments, the anti-CD33 scFv comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:2, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:3, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:4. H 5, CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7. L Includes.

[0188] In certain embodiments, the anti-CD33 scFv comprises the amino acid sequence set forth in SEQ ID NO:8. H and V comprising the amino acid sequence set forth in SEQ ID NO:92. L In certain embodiments, V H and V L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 105.

[0189] In certain embodiments, the heavy chain variable region (V H ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: H -V L In certain embodiments, the light chain variable region (V L ) is positioned at the N-terminus. In certain embodiments, the variable region is positioned from the N-terminus to the C-terminus: L -V H . [Table 11]

[0190] Monoclonal Antibodies The presently disclosed subject matter provides antibodies (e.g., human antibodies, e.g., human monoclonal antibodies) that specifically bind to CD33 (e.g., human CD33). The V of anti-CD33 antibodies 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 H The amino acid sequences are set forth in SEQ ID NOs: 8, 18, 28, 35, 43, 52, 62, 72, 81, and 88. V of 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 L The amino acid sequences are set forth in SEQ ID NOs: 9, 19, 29, 44, 53, 63, 73, 82, 89, and 92.

[0191] Considering that each of the 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 antibodies can bind to CD33, H and V LSequences can be "mixed and matched" to create other anti-CD33 binding molecules. CD33 binding of such "mixed and matched" antibodies can be tested using binding assays known in the art, including, for example, ELISAs, Western blots, RIAs, Biacore analysis. H and V L When chains are mixed and matched, a particular V H / V L V from involution H The sequence is structurally similar to V H Similarly, a particular V H / V L V from involution L The sequence is structurally similar to V L It is replaced by an array.

[0192] In certain embodiments, the subject matter disclosed herein provides a polypeptide comprising (a) a heavy chain variable region (V) comprising an amino acid sequence selected from SEQ ID NOs: 8, 18, 28, 35, 43, 52, 62, 72, 81, and 88; H ), and (b) a light chain variable region (V L ), wherein the antibody or antigen-binding fragment specifically binds to CD33, e.g., human CD33. H and V L teeth, (a) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9; (b) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 18, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 19; (c) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 28, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 29; (d) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 35, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 29; (e) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 43, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 44; (f) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 52, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 53; (g) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 62, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 63; (h) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 72, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 73; (i) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 81, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 82; (j) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 88, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 89; and (k) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:92.

[0193] In certain embodiments, the subject matter disclosed herein provides antibodies or antigen-binding fragments thereof comprising the heavy and light chain CDR1, CDR2 and CDR3 of 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3.

[0194] V of 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 H The amino acid sequences of CDR1 are set forth in SEQ ID NOs: 2, 12, 22, 32, 37, 47, 56, 66, 76, and 85. The V of 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 antibodies HThe amino acid sequences of CDR2 are set forth in SEQ ID NOs: 3, 13, 23, 33, 38, 57, 67, and 86. The V of 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 H The amino acid sequences of CDR3 are set forth in SEQ ID NOs: 4, 14, 24, 34, 39, 48, 58, 68, 77, and 87.

[0195] V of 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 L The amino acid sequences of CDR1 are set forth in SEQ ID NOs: 5, 15, 25, 40, 49, 59, 69, and 78. The V of 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 L The amino acid sequences of CDR2 are set forth in SEQ ID NOs: 6, 16, 26, 41, 50, 60, 70, and 79. The V of 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 L The amino acid sequences of CDR3 are set forth in SEQ ID NOs: 7, 17, 27, 42, 51, 61, 71, and 80. The CDR regions are delineated using the IMGT system. In certain embodiments, the CDR regions are delineated using the IMGT numbering system, accessible at http: / / www.imgt.org / IMGT_vquest / input.

[0196] Given that each of these antibodies or antigen-binding fragments thereof is capable of binding to CD33, and that the antigen-binding specificity is provided primarily by the CDR1, CDR2, and CDR3 regions, V H CDR1 sequence, V H CDR2 sequence, V H and CDR3 sequence and V L CDR1 sequence, V L CDR2 sequence, and V LCDR3 sequences can be "mixed and matched" to create other anti-CD33 binding molecules (i.e., CDRs from different antibodies can be mixed and matched, but each antibody must have the same V H CDR1, V H CDR2, and V H CDR3 and V L CDR1, V L CDR2, and V L CDR3). CD33 binding of such "mixed and matched" antibodies can be tested using the binding assays described above. H When CDR sequences are mixed and matched, a particular V H The CDR1, CDR2, and / or CDR3 sequences from the sequence are replaced with a structurally similar CDR sequence(s). L When CDR sequences are mixed and matched, a particular V L The CDR1, CDR2, and / or CDR3 sequences from the sequences are preferably replaced with structurally similar CDR sequence(s). One or more V sequences having structurally similar sequences from the CDR sequences of the antibodies or antigen-binding fragments thereof disclosed herein, 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3, are preferably replaced with structurally similar CDR sequence(s). H CDR region sequence and / or V L By replacing the CDR region sequences, a new V H Sequence and V L It will be readily apparent to one skilled in the art that sequences can be made.

[0197] In certain embodiments, the subject matter disclosed herein comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 22, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 56, SEQ ID NO: 66, SEQ ID NO: 76, or SEQ ID NO: 85; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:13, SEQ ID NO:23, SEQ ID NO:33, SEQ ID NO:38, SEQ ID NO:57, SEQ ID NO:67, or SEQ ID NO:86; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 4, SEQ ID NO: 14, SEQ ID NO: 24, SEQ ID NO: 34, SEQ ID NO: 39, SEQ ID NO: 48, SEQ ID NO: 58, SEQ ID NO: 68, SEQ ID NO: 77, or SEQ ID NO: 87; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:15, SEQ ID NO:25, SEQ ID NO:40, SEQ ID NO:49, SEQ ID NO:59, SEQ ID NO:69, or SEQ ID NO:78; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, SEQ ID NO:16, SEQ ID NO:26, SEQ ID NO:41, SEQ ID NO:50, SEQ ID NO:60, SEQ ID NO:70, or SEQ ID NO:79; and (f) providing an antibody or an antigen-binding fragment thereof comprising a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7, SEQ ID NO:17, SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:51, SEQ ID NO:61, SEQ ID NO:71, or SEQ ID NO:80;

[0198] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:2; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:3; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:4; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7.

[0199] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:17.

[0200] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:27.

[0201] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:27.

[0202] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 40; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42.

[0203] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 47; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 49; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 50; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:51.

[0204] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 56; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 58; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:59; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 60; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO:61.

[0205] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 66; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 67; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71.

[0206] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 76; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 77; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 78; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 79; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 80.

[0207] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 85; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 87; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42.

[0208] In certain embodiments, the anti-CD33 antibody, or antigen-binding fragment thereof, comprises a heavy chain constant region and / or a light chain constant region.

[0209] In certain embodiments, the heavy chain constant region comprises an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 95. In certain embodiments, the heavy chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 95. SEQ ID NO: 95 is provided below. ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK [SEQ ID NO: 95]

[0210] In certain embodiments, the light chain constant region comprises an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 96. In certain embodiments, the light chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 96. SEQ ID NO: 96 is provided below. RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC [SEQ ID NO: 96]

[0211] In certain embodiments, the light chain constant region comprises an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 99. In certain embodiments, the light chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 99. SEQ ID NO: 99 is provided below. GQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS [SEQ ID NO: 99]

[0212] In certain embodiments, an anti-CD33 antibody or antigen-binding fragment thereof comprises (a) a heavy chain constant region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 95, and (b) a light chain constant region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 96. In certain embodiments, an anti-CD33 antibody or antigen-binding fragment thereof comprises (a) a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 95, and (b) a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 96.

[0213] In certain embodiments, an anti-CD33 antibody or antigen-binding fragment thereof comprises (a) a heavy chain constant region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 95, and (b) a light chain constant region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 99. In certain embodiments, an anti-CD33 antibody or antigen-binding fragment thereof comprises (a) a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 95, and (b) a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 99.

[0214] In certain embodiments, an anti-CD33 antibody or antigen-binding fragment thereof comprises a heavy chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 97. In certain embodiments, an anti-CD33 antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 97. SEQ ID NO: 97 is provided below. EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVSAISGRGGSTYYTDSVKGRFTISRDNSKNTVSLQMNSLRAEDTAVYYCAGRGDYYYYYGMDVWGQG TTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK [SEQ ID NO: 97]

[0215] In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof comprises a light chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 98. In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 98. SEQ ID NO: 98 is provided below. DIVMTQSPLSSPVTLGQPASFSCRSSQSLVYSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCMQSTQFPHTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC [SEQ ID NO: 98]

[0216] In certain embodiments, an anti-CD33 antibody or antigen-binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 97, and (b) a light chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 98. In certain embodiments, an anti-CD33 antibody or antigen-binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 97, and (b) a light chain comprising the amino acid sequence set forth in SEQ ID NO: 98.

[0217] In certain embodiments, an anti-CD33 antibody, or antigen-binding fragment thereof, comprises a heavy chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 100. In certain embodiments, an anti-CD33 antibody, or antigen-binding fragment thereof, comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 100. SEQ ID NO: 100 is provided below. EVHLLESGGGLVQPGGSLRLSCAASGFIFSSNAMSWVRQAPGKGLEWVSAISGYGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWGTYIVGATGDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK [SEQ ID NO: 100]

[0218] In certain embodiments, the anti-CD33 antibody, or antigen-binding fragment thereof, comprises a light chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 101. In certain embodiments, the anti-CD33 antibody, or antigen-binding fragment thereof, comprises a light chain comprising an amino acid sequence set forth in SEQ ID NO: 101. SEQ ID NO: 101 is provided below. QSALTQPPSASGSPGQSVTISCTGTSNDVGGYNYVSWYQQHPGKAPKLLIYEVSKRPSGVPDRFSGSQSGNTASLTVSGLQAEDEADYYCSSYAGSNNWVFGGGTKLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS [SEQ ID NO: 101]

[0219] In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 100, and (b) a light chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 101. In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof comprises (a) a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 100, and (b) a light chain comprising the amino acid sequence set forth in SEQ ID NO: 101.

[0220] In certain embodiments, an anti-CD33 antibody or antigen-binding fragment thereof comprises a heavy chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 102. In certain embodiments, an anti-CD33 antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 102. SEQ ID NO: 102 is provided below. QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYFRSKWYNVYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCASEGGSYYDHWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK [SEQ ID NO: 102]

[0221] In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof comprises a light chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 103. In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 103. SEQ ID NO: 103 is provided below. DIQMTQSPSSVSASVGDRVTITCRASQGISNWLTWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQADSFPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC [SEQ ID NO: 103]

[0222] In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 100, and (b) a light chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 102. In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof comprises (a) a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 100, and (b) a light chain comprising the amino acid sequence set forth in SEQ ID NO: 103.

[0223] The constant / framework regions of the anti-CD33 antibodies disclosed herein can be altered, for example, by amino acid substitutions, to modify the properties of the antibody (e.g., to increase or decrease one or more of antigen binding affinity, Fc receptor binding, antibody carbohydrate, e.g., glycosylation, fucosylation, etc., number of cysteine ​​residues, effector cell function, complement function, or introduction of conjugation sites).

[0224] In certain embodiments, the anti-CD33 antibodies disclosed herein are fully human antibodies, such as any one of 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3. Fully human mAbs cause severe side effects when administered to humans, including anaphylaxis and hypersensitivity reactions.

[0225] The use of phage display libraries has allowed the selection of large antibody repertoires for unique and rare Abs against highly defined epitopes (for details on phage display, see McCafferty et al., Phage antibodies: filamentous phage displaying antibody variable domains. Nature, 348:552-554). Thus, it has become possible to rapidly identify human Fab or single-chain Fv (scFv) fragments that are highly specific for tumor antigen-derived peptide-MHC complex molecules. In addition, by using Fab fragments to engineer full-length monoclonal antibodies (mAbs), it is possible to directly generate therapeutic human mAbs, avoiding the several months of time-consuming work that is usually required to develop therapeutic mAbs. The subject matter disclosed herein includes the development of fully human mAbs that recognize, for example, human CD33 polypeptides (e.g., polypeptides having the amino acid sequence set forth in SEQ ID NO: 116) for cancer therapy.

[0226] 5.3.3.Homologous antibodies In certain embodiments, the anti-CD33 antibodies, or antigen-binding fragments thereof, disclosed herein comprise heavy and light chain variable regions that comprise amino acid sequences that are homologous or identical to the amino acid sequences of the antibodies described herein (e.g., 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 antibodies), and the antibodies, or antigen-binding fragments thereof, retain the desired functional properties of the anti-CD33 antibodies, or antigen-binding fragments thereof, of the subject matter disclosed herein.

[0227] For example, the presently disclosed subject matter provides an anti-CD33 antibody, or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, (a) the heavy chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:18, SEQ ID NO:28, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:72, SEQ ID NO:81, or SEQ ID NO:88; (b) the light chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:19, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:63, SEQ ID NO:73, SEQ ID NO:82, SEQ ID NO:89, or SEQ ID NO:92.

[0228] In certain embodiments, V H Amino acid sequence and / or V L The amino acid sequence can be at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the sequences set forth above. H and V L V with high (i.e., 80% or more) homology or identity to the region H and V L Antibodies having regions can be obtained by mutagenesis (e.g., site-directed or PCR-mediated mutagenesis) followed by testing of the encoded modified antibody for retained functionality (i.e., binding affinity) using the binding assays described herein.

[0229] In certain embodiments, the anti-CD33 antibodies, or antigen-binding fragments thereof, disclosed herein comprise heavy and light chain constant regions that comprise amino acid sequences that are homologous or identical to the amino acid sequences of the antibodies described herein (e.g., 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 antibodies), and the antibodies, or antigen-binding fragments thereof, retain the desired functional properties of the anti-CD33 antibodies, or antigen-binding fragments thereof, of the subject matter disclosed herein.

[0230] For example, the presently disclosed subject matter provides an anti-CD33 antibody, or antigen-binding fragment thereof, comprising a heavy chain constant region and a light chain constant region, (a) Heavy chain constant region (C H ) comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the amino acid sequence set forth in SEQ ID NO:95; (b) Light chain constant region (C L ) comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:96, or SEQ ID NO:99.

[0231] In certain embodiments, C H Amino acid sequence and / or C L The amino acid sequence may be at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the above sequences. H and C L C that has high (i.e., 80% or more) homology or identity with the regionH and C L Antibodies having regions can be obtained by mutagenesis (e.g., site-directed or PCR-mediated mutagenesis) followed by testing of the encoded modified antibody for retained functionality (i.e., binding affinity) using the binding assays described herein.

[0232] As used herein, the percentage of homology between two amino acid sequences is equal to the percentage of identity between the two sequences. The percentage of identity or homology between two sequences is a function of the number of identical positions shared by the two sequences (i.e., % homology = number of identical positions / total number of positions x 100), taking into account the number of gaps that need to be introduced for optimal alignment of the two sequences and the length of each gap. The comparison of sequences and the determination of the percentage of identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.

[0233] The percent homology or identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput Appl Biosci (1988); 14:11-17) as implemented in the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch (J Mol Biol (1970); 48:444-453) as implemented in the GAP program in the GCG software package (available at www.gcg.com) using either a Blossum 62 matrix or a PAM250 matrix, and gap weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6.

[0234] Additionally or alternatively, the protein sequences of the subject matter disclosed herein can further be used as a "query sequence" to perform searches against public databases, for example to identify related sequences. Such searches can be performed using the XBLAST program (version 2.0) of Altschul et al., J Mol Biol (1990); 215:403-10. To obtain amino acid sequences homologous to the antibody molecules of the present invention, BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., Nucleic Acids Res (1997); 25(17):3389-3402. When utilizing BLAST, Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

[0235] 5.3.4. Antibodies with Conservative Modifications In certain embodiments, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein comprise a heavy chain variable region comprising a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence, and a light chain variable region comprising a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence, where one or more of these CDR sequences comprise a specific amino acid sequence based on the preferred antibodies described herein (e.g., 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 antibodies), or conservative modifications thereof, and the antibody retains the desired functional properties of the anti-CD33 antibodies or antigen-binding fragments thereof of the presently disclosed subject matter. The presently disclosed subject matter provides an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence, and a light chain variable region comprising a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence, (a) the CDR3 sequence of the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NOs: 4, 14, 24, 34, 39, 48, 58, 68, 77, and 87, and conservative modifications thereof; (b) the CDR3 sequence of the light chain variable region comprises an amino acid sequence selected from SEQ ID NOs: 7, 17, 27, 42, 51, 61, 71, and 80, and conservative modifications thereof.

[0236] In certain embodiments, the heavy chain variable region CDR3 sequence comprises an amino acid sequence selected from SEQ ID NOs: 4, 14, 24, 34, 39, 48, 58, 68, 77, and 87, and conservative modifications thereof, and the light chain variable region CDR3 sequence comprises an amino acid sequence selected from SEQ ID NOs: 7, 17, 27, 42, 51, 61, 71, and 80, and conservative modifications thereof.

[0237] In certain embodiments, the heavy chain variable region CDR2 sequence comprises an amino acid sequence selected from SEQ ID NOs: 3, 13, 23, 33, 38, 57, 67, and 86, and conservative modifications thereof, and the light chain variable region CDR2 sequence comprises an amino acid sequence selected from SEQ ID NOs: 6, 16, 26, 41, 50, 60, 70, and 79, and conservative modifications thereof.

[0238] In certain embodiments, the heavy chain variable region CDR1 sequence comprises an amino acid sequence selected from SEQ ID NOs: 2, 12, 22, 32, 37, 47, 56, 66, 76, and 85, and conservative modifications thereof, and the light chain variable region CDR1 sequence comprises an amino acid sequence selected from SEQ ID NOs: 5, 15, 25, 40, 49, 59, 69, and 78, and conservative modifications thereof.

[0239] As used herein, the term "conservative sequence modifications" is intended to refer to amino acid modifications that do not significantly affect or significantly change the binding characteristics of the antibody containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into the antibodies of the present disclosure by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis.

[0240] A conservative amino acid substitution is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. Exemplary conservative amino acid substitutions are shown in Table 24. Amino acid substitutions can be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC. In certain embodiments, the sequences disclosed herein, e.g., CDR sequences, V H Sequence or V L The sequence can have up to about 1, up to about 2, up to about 3, up to about 4, up to about 5, up to about 6, up to about 7, up to about 8, up to about 9, or up to about 10 modified and / or substituted amino acid residues. [Table 12]

[0241] Amino acids can be grouped according to common side chain properties. Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile, ●Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln, ●Acidic: Asp, Glu, ●Basic: His, Lys, Arg, Residues that affect chain orientation: Gly, Pro, ●Aromatics: Trp, Tyr, Phe.

[0242] Non-conservative substitutions involve exchanging a member of one of these classes for a member of another class.

[0243] 5.3.5. ANTI-CD33 ANTIBODIES THAT CROSS-COMPETE FOR BINDING TO CD33 WITH ANTI-CD33 ANTIBODIES OF THE PRESENT DISCLOSURE The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that cross-compete with any of the disclosed anti-CD33 antibodies for binding to CD33 (e.g., human CD33). For example, and without limitation, a cross-competing antibody can bind to the same epitope region, e.g., the same epitope, adjacent epitopes, or overlapping, as any of the presently disclosed subject matter anti-CD33 antibodies or antigen-binding fragments thereof. In certain embodiments, a reference antibody or reference antigen-binding fragment thereof for cross-competition studies can be any one of the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein, e.g., 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 antibodies.

[0244] Such cross-competing antibodies can be identified based on their ability to cross-compete with any one of the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein in standard CD33 binding assays. For example, Biacore analysis, ELISA assays or flow cytometry can be used to demonstrate cross-competition with the antibodies of the presently disclosed subject matter. The ability of the test antibody to inhibit the binding of, for example, any one of the anti-CD33 antibodies disclosed herein (e.g., 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 antibodies) to CD33 (e.g., human CD33) demonstrates that the test antibody can compete with any one of the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein for binding to CD33 (e.g., human CD33) and thus bind to the same epitope region on CD33 (e.g., human CD33) as any one of the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein. In certain embodiments, the cross-competing antibody or antigen-binding fragment thereof binds to the same epitope on CD33 (e.g., human CD33) as any one of the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein.

[0245] 5.3.6. Characterization of Antibody Binding to Antigen The subject antibodies or antigen-binding fragments thereof disclosed herein can be tested for binding to CD33, for example, by standard ELISA. To determine whether selected anti-CD33 antibodies bind to unique epitopes, each antibody can be biotinylated using commercially available reagents (Pierce, Rockford, IL). Competition studies using unlabeled and biotinylated monoclonal antibodies can be performed using the CD33-coated ELISA plates described above. Biotinylated mAb binding can be detected with a strep-avidin-alkaline phosphatase probe.

[0246] To determine the isotype of purified antibodies, isotype ELISAs can be performed using reagents specific for antibodies of a particular isotype. Anti-CD33 human IgG can be further tested for reactivity with the CD33 antigen by Western blotting.

[0247] In certain embodiments, K D is measured by radiolabeled antigen binding assay (RIA). In certain embodiments, the RIA is performed using a Fab version of the antibody of interest and its antigen. For example, the solution binding affinity of the Fab for the antigen is measured by binding the Fab to a minimum concentration of ( 125 I) It is measured by equilibration with labeled antigen and then capturing bound antigen with a plate coated with an anti-Fab antibody (see, e.g., Chen et al., J Mol Biol (1999); 293:865-881).

[0248] In certain embodiments, K D is measured using a BIACORE® surface plasmon resonance assay, such as an assay using a BIACORE®-2000 or BIACORE®-3000 (BIAcore, Inc., Piscataway, NJ).

[0249] 5.3.7. Immunoconjugates The presently disclosed subject matter provides anti-CD33 antibodies or antigen-binding fragments thereof conjugated to a therapeutic moiety, such as a cytotoxin, a drug (e.g., an immunosuppressant), or a radiotoxin. Such conjugates are referred to herein as "immunoconjugates." Immunoconjugates that include one or more cytotoxins are referred to as "immunotoxins." A cytotoxin or cytotoxic agent includes any agent that is detrimental to (e.g., kills) a cell. Non-limiting examples of cytotoxins include taxol (such as ricin, diphtheria, gelonin), cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin, as well as analogs or homologs thereof. In addition, examples of therapeutic agents include calicheamicin, aureastatin, metabolic antagonists (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepaclorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomatin, and the like). These include isin C, and cis-dichlorodiamineplatinum(II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), hypomethylating agents (azacytidine and decitabine), and antimitotic agents (e.g., vincristine and vinblastine).

[0250] Other examples of therapeutic cytotoxins that can be conjugated to the anti-CD33 antibodies disclosed herein include duocarmycin, calicheamicin, maytansine, and auristatin, and derivatives thereof. Cytotoxins can be conjugated to the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein using linker technology available in the art. Examples of linker types that have been used to conjugate cytotoxins to antibodies include, but are not limited to, hydrazones, thioethers, esters, disulfides, and peptide-containing linkers. Linkers can be selected that are susceptible to cleavage, for example, by low pH in lysosomal compartments or by proteases preferentially expressed in tumor tissues, such as cathepsins (e.g., cathepsin B, C, D). For further discussion of the types of cytotoxins, linkers and methods for conjugating therapeutic agents to antibodies, see also Saito, G. et al. (2003) Adv. Drug Deliv. Rev. 55:199-215; Trail, PA et al. (2003) Cancer Immunol. Immunother. 52:328-337; Payne, G. (2003) Cancer Cell 3:207-212; Allen, TM (2002) Nat. Rev. Cancer 2:750-763; Pastan, I. and Kreitman, RJ (2002) Curr. Opin. Investig. Drugs 3:1089-1091; Senter, PD and Springer, CJ (2001) Adv. Drug Deliv. Rev. 53:247-264.

[0251] The anti-CD33 antibodies or antigen-binding fragments thereof of the presently disclosed subject matter can also be conjugated to radioisotopes to generate cytotoxic radiopharmaceuticals, also referred to as radioimmunoconjugates. Non-limiting examples of radioisotopes that can be conjugated to antibodies for diagnostic or therapeutic use include: 47 Sc, 67 Cu, 90 Y, 131 I,149 Tb, 161 Tb, 177 Lu, 225 Ac, 213 Bi, 223 Ra and 227 Th. Methods for preparing radioimmunoconjugates are established in the art. Examples of radioimmunoconjugates include Zevalin™ (IDEC Pharmaceuticals) and Bexxar™ (Corixa Pharmaceuticals), which are commercially available, and similar methods can be used to prepare radioimmunoconjugates using anti-CD33 antibodies disclosed herein.

[0252] In certain embodiments, an anti-CD33 antibody or antigen-binding fragment thereof of the presently disclosed subject matter can be conjugated to a radioisotope and a chelating agent can be used to generate a radioimmunoconjugate. As used herein, the term "chelating agent" refers to a compound in the form of a heterocyclic ring or surrounding structure that contains a metal ion bound by coordinate bonds to at least two nonmetallic ions. Non-limiting examples of chelating agents include 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), 2,2'-(7-(1-carboxy-4-((4-isothiocyanatobenzyl)amino)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (NODA), 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA), diethylenetriamine-N,N,N',N,N-pentaacetic acid, pentetic acid, (carboxymethyl)-1,4,7-triazonane-1,4-diyl, pent ... 2-pyridinol-1-oxide (HOPO), N-(5-(3-((5-aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid (DFO), and 2-[1,4,7-triazacyclononan-1-yl-4,7-bis(tBu-ester)]-1,5-pentanedioic acid (NODAGA).Additional exemplary chelating agents encompassed by the presently disclosed subject matter include AAZTA and its derivatives, BAT, BARAC, BPCA, TE2A, CB-TE2A, CB0TE1A1P, CB-TE2P, MM-TE2A, DM TE-2A, CP356, DATA, DBCO, DiAmSar and its derivatives, DIBO, DIMA, DFO, DGO, DOTA and its derivatives (e.g., Ac-DOTA, benzo-DOTA, dibenzo-DOTA, CB-DO2A, 3p-C-DEPA, oxo-DO3A), its DOTMA derivatives (e.g., benzo-DOTMA), DTPA and its derivatives (e.g., benzo-DTPA, dibenzo-DTPA, phenyl-DTPA, diphenyl-DTPA, benzyl-DTPA, dibenzyl-DTPA, 1B4M-DTPA, CHX-A''-DTPA), EDTA, EGTA, EHPG and its derivatives (e.g., 5-Cl-EHPG, 5-Br-E HPG, 5-Me-EHPG, 5t-Bu-EHPG, 5-sec-Bu-EHPG), H2dedpa, H4octapa, H2azapa, H5decapa, H6phospa, HBED and its derivatives, SHBED, HEHA, HYNIC, LICAM and its derivatives, MECAM, NODASA, NODAGA, NOPO, NOTA and its derivatives (e.g., benzo-NOTA), NETA, PEPA, PCTA, PDTA, TACN-TM, TCMC, TETA and its derivatives (e.g., benzo-TETA), TETMA and its derivatives (e.g., benzo-TETMA), TRAP (PRP9), TRITA, TTHA and its derivatives. The antibody conjugates of the subject matter disclosed herein can be used to modify a given biological response, and the drug moiety should not be construed as being limited to classical chemotherapeutic agents. For example, the drug moiety can be a protein or polypeptide having a desired biological activity.Such proteins can include, for example, enzymatically active toxins, or active fragments thereof (e.g., abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin), proteins (e.g., tumor necrosis factor (TNF) or interferon-γ), or biological response modifiers (e.g., lymphokines, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), or other growth factors).

[0253] Techniques for conjugating such therapeutic moieties to antibodies are well known and are described, for example, in Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of Therapeutic Agents In Cancer Therapy: A Review", Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); See, Therapeutic Use Of Radiolabeled Antibodies In Cancer Therapy”, Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., “The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates”, Immunol. Rev., 62:119-58 (1982).

[0254] 5.3.8. Multispecific molecules The subject matter disclosed herein provides multispecific molecules comprising the anti-CD33 antibodies disclosed herein, or fragments thereof. The antibodies disclosed herein or antigen-binding fragments thereof can be derivatized or linked to one or more functional molecules, such as one or more peptides or proteins (e.g., one or more antibodies or ligands for a receptor), to generate multispecific molecules that bind to two or more different binding sites or target molecules. The anti-CD33 antibodies disclosed herein or antigen-binding fragments thereof can in fact be derivatized or linked to two or more other functional molecules to generate multispecific molecules that bind to more than two different binding sites and / or target molecules. To generate multispecific molecules, the anti-CD33 antibodies disclosed herein or antigen-binding fragments thereof can be functionally linked (e.g., by chemical conjugation, genetic fusion, non-covalent association, or other methods) to one or more other binding molecules, such as another antibody, antibody fragment, peptide, or binding mimetic, resulting in a bispecific molecule.

[0255] In certain embodiments, the multispecific molecule is a bispecific molecule. In certain embodiments, the bispecific molecule comprises at least a first binding specificity for CD33 and a second binding specificity for a second target epitope region. The second target epitope region can be a CD33 epitope or a non-CD33 epitope, e.g., a different antigen. In certain embodiments, the multispecific molecule comprises a first binding specificity for CD33, a second binding specificity for a second target, and a third binding specificity for a third target. In certain embodiments, the second target is an antigen expressed on the surface of an immune cell (e.g., a T cell, or a human immune effector cell). In certain embodiments, the multispecific molecule can recruit the activity of a human immune effector cell by specifically binding to an effector antigen on the immune effector cell, thereby enhancing effector function. In certain embodiments, the third target is an antigen expressed on a senescent cell.

[0256] The multispecific molecules of the presently disclosed subject matter can be prepared by conjugating the component binding specificities using methods known in the art. For example, each binding specificity of the multispecific molecule can be generated separately and then conjugated to each other. When the binding specificities are proteins or peptides, a variety of coupling or cross-linking agents can be used for covalent conjugation. Non-limiting examples of cross-linking agents include protein A, carbodiimide, N-succinimidyl-S-acetyl-thioacetate (SATA), 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), and sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) (see, e.g., Karpovsky et al. (1984) J. Exp. Med. 160:1686; Liu, MA et al. (1985) Proc. Natl. Acad. Sci. USA 82:8648). Other methods include those described by Paulus (1985) Behring Ins. Mitt. No. 78, 118-132, Brennan et al. (1985) Science 229:81-83), and Glennie et al. (1987) J. Immunol. 139:2367-2375. Conjugating agents can be SATA and sulfo-SMCC, both available from Pierce Chemical Co. (Rockford, IL).

[0257] When the binding specificities are antibodies, they can be conjugated via sulfhydryl bonds in the C-terminal hinge regions of the two heavy chains. In certain embodiments, the hinge region is modified to contain an odd number of sulfhydryl residues, preferably one, prior to conjugation.

[0258] Alternatively, both binding specificities can be encoded in the same vector and expressed and assembled in the same host cell. This method allows multispecific molecules to be produced in the form of mAb x mAb, mAb x Fab, Fab x F(ab') 2 , or Ligand x Fab fusion proteins.

[0259] Binding of multispecific molecules to their specific targets can be confirmed, for example, by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), FACS analysis, bioassay (e.g., growth inhibition), or Western blot assay. Each of these assays generally detects the presence of a particular protein-antibody complex of interest by using a labeled reagent (e.g., an antibody) specific for the complex of interest. Alternatively, the complex can be detected using any of a variety of other immunoassays. For example, antibodies can be radioactively labeled and used in a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986, incorporated herein by reference). Radioisotopes can be detected by such means as the use of a gamma counter or a scintillation counter, or by autoradioassay testing.

[0260] 5.4. Antibodies or antigen-binding fragments and / or V H and / or V L Nucleic acid encoding The presently disclosed subject matter provides nucleic acids encoding the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein. The presently disclosed subject matter provides nucleic acids encoding the heavy chain variable region sequence of any one of the anti-CD33 antibodies disclosed herein (e.g., 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 antibodies). In certain embodiments, the nucleic acid comprises or consists of a nucleotide sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the nucleotide sequence set forth in SEQ ID NO: 10, SEQ ID NO: 20, SEQ ID NO: 30, SEQ ID NO: 36, SEQ ID NO: 45, SEQ ID NO: 54, SEQ ID NO: 64, SEQ ID NO: 74, SEQ ID NO: 83, SEQ ID NO: 90, or SEQ ID NO: 93. In certain embodiments, the nucleic acid comprises or consists of the nucleotide sequence set forth in SEQ ID NO: 10, SEQ ID NO: 20, SEQ ID NO: 30, SEQ ID NO: 36, SEQ ID NO: 45, SEQ ID NO: 54, SEQ ID NO: 64, SEQ ID NO: 74, SEQ ID NO: 83, SEQ ID NO: 90, or SEQ ID NO: 93.

[0261] The presently disclosed subject matter provides a nucleic acid encoding the light chain variable region sequence of any one of the anti-CD33 antibodies disclosed herein (e.g., 3-P14, 4-B2, 1-J19, 1-J19-2, 1-P13, 1-P23, 1-A20, 2-N3, 1-H19, 2-F18, and 4-P3 antibodies). In certain embodiments, the nucleic acid comprises or consists of a nucleotide sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the nucleotide sequence set forth in SEQ ID NO:11, SEQ ID NO:21, SEQ ID NO:31, SEQ ID NO:46, SEQ ID NO:55, SEQ ID NO:65, SEQ ID NO:75, SEQ ID NO:84, SEQ ID NO:91, or SEQ ID NO:94. In certain embodiments, the nucleic acid comprises or consists of the nucleotide sequence set forth in SEQ ID NO:11, SEQ ID NO:21, SEQ ID NO:31, SEQ ID NO:46, SEQ ID NO:55, SEQ ID NO:65, SEQ ID NO:75, SEQ ID NO:84, SEQ ID NO:91, or SEQ ID NO:94. Further provided are vectors comprising the nucleic acids disclosed herein. In certain embodiments, the vector is an expression vector. The presently disclosed subject matter further provides a host cell comprising the vector disclosed herein. In certain embodiments, the host cell is a T cell.

[0262] 5.5. Pharmaceutical Compositions and Methods of Treatment The presently disclosed subject matter provides compositions comprising an anti-CD33 antibody or antigen-binding fragment thereof disclosed herein, an immunoconjugate disclosed herein, a multispecific molecule disclosed herein, In certain embodiments, the composition is a pharmaceutical composition further comprising a pharma- ceutically acceptable carrier.

[0263] Suitable pharma- ceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, as well as combinations thereof. The pharma-ceutically acceptable carriers may further contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, preservatives, or buffers, which enhance the shelf life or effectiveness of the binding protein. The compositions for injection can be formulated to provide quick, sustained, or delayed release of the active ingredient after administration to a mammal, as is well known in the art.

[0264] The subject matter disclosed herein provides various methods of using the anti-CD33 antibodies or antigen-binding fragments thereof, immunoconjugates, multispecific molecules, and compositions disclosed herein. For example, the subject matter disclosed herein provides a method for treating or ameliorating a disease or disorder in a subject. In certain embodiments, the method comprises administering to the subject one or more of the anti-CD33 antibodies or antigen-binding fragments thereof, immunoconjugates, multispecific molecules, or compositions disclosed herein. In certain embodiments, the disease or disorder is associated with CD33. In certain embodiments, the disease or disorder is associated with overexpression of CD33. In certain embodiments, the disease or disorder is a tumor.

[0265] The subject matter disclosed herein provides a method of reducing tumor burden in a subject. In certain embodiments, the method comprises administering to the subject one or more of an anti-CD33 antibody or antigen-binding fragment thereof, an immunoconjugate, a multispecific molecule, or a composition disclosed herein. The anti-CD33 antibody or antigen-binding fragment thereof disclosed herein can reduce the number of tumor cells, reduce tumor size, and / or eradicate tumors in the subject.

[0266] The subject matter disclosed herein also provides a method for increasing or extending the survival time of a subject with a tumor. In certain embodiments, the method comprises administering to the subject one or more of an anti-CD33 antibody or antigen-binding fragment thereof, an immunoconjugate, a multispecific molecule, or a composition disclosed herein. The method can reduce or eradicate the tumor burden in the subject.

[0267] The subject matter disclosed herein further provides methods for treating and / or preventing a tumor in a subject, in certain embodiments, the method comprises administering to the subject one or more of an anti-CD33 antibody or antigen-binding fragment thereof, immunoconjugate, multispecific molecule, or composition disclosed herein.

[0268] Such methods include administering an effective amount of an anti-CD33 antibody or antigen-binding fragment thereof disclosed herein, a composition (e.g., a pharmaceutical composition) disclosed herein to achieve the desired effect, whether amelioration of an existing condition or prevention of recurrence. For treatment, the dosage is an amount effective to produce the desired effect. An effective amount can be provided in a single dose or in a series of doses. An effective amount can be provided in a bolus or by continuous perfusion.

[0269] In certain embodiments, the tumor is cancer. In certain embodiments, the tumor is selected from the group consisting of hematological cancer and solid tissue cancer. In certain embodiments, the hematological cancer is selected from the group consisting of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), myeloproliferative neoplasms (MPN), and chronic myeloid neoplasms. In certain embodiments, the tumor is acute myeloid leukemia AML.

[0270] Any suitable method or route can be used to administer the anti-CD33 antibody disclosed herein, and optionally co-administer the anti-tumor agent. Routes of administration include, but are not limited to, oral, intravenous, intraperitoneal, subcutaneous, intramuscular, intranodal, intratumoral, intraosseous, intrathecal, pleural, intrapleural, topical, and direct administration. However, it should be emphasized that the subject matter disclosed herein is not limited to any particular method or route of administration.

[0271] The anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein can be administered as conjugates that specifically bind to a receptor and deliver a toxic and lethal payload following ligand-toxin internalization.

[0272] 5.6. Diagnostic and prognostic methods The anti-CD33 antibodies, antigen-binding fragments thereof, multispecific molecules, and nucleic acids encoding them disclosed herein can be used in diagnostic and prognostic applications, as well as research tools for the detection of CD33 in biological samples, cells, tissues, or blood samples. The subject matter disclosed herein provides a method for detecting CD33 in a cell, tissue, or blood sample. In certain embodiments, the method includes contacting a cell, tissue, or blood sample with an antibody, antigen-binding fragment thereof, or multispecific molecule disclosed herein, where the antibody, antigen-binding fragment thereof, or multispecific molecule comprises a detectable label, and determining the amount of the labeled antibody, antigen-binding fragment thereof, or multispecific molecule bound to the cell, tissue, or blood sample by measuring the amount of detectable label associated with the cell, tissue, or blood sample, where the amount of bound antibody, antigen-binding fragment thereof, or multispecific molecule indicates the amount of CD33 in the cell, tissue, or blood sample. The cell or tissue can be any cell or tissue, including any normal, healthy, or cancerous cell and tissue. In certain embodiments, the blood sample is a peripheral blood sample.

[0273] The anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein can be used in methods known in the art relating to localization and / or quantification of CD33 polypeptides (e.g., for use in measuring levels of CD33 protein in an appropriate physiological sample, for use in diagnostic methods, for use in imaging of the polypeptide, etc.). The anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein can be used to isolate CD33 polypeptides by standard techniques such as affinity chromatography or immunoprecipitation. The anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein can facilitate purification of native immunoreactivity.

[0274] CD33 protein from biological samples, such as mammalian serum or cells, as well as recombinantly produced immunoreactive CD33 protein expressed in a host system. Additionally, the anti-CD33 antibodies of the present technology can be used to detect immunoreactive CD33 protein (e.g., in plasma, cell lysates, or cell supernatants) to assess the abundance and expression pattern of the immunoreactive polypeptide. The anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein can be used diagnostically to monitor immunoreactive CD33 protein levels in tissues as part of a clinical trial procedure, for example, to determine the effectiveness of a given therapeutic regimen. As mentioned above, detection can be facilitated by coupling (i.e., physically linking) the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein to a detectable substance.

[0275] An exemplary method for detecting the presence or absence of immunoreactive CD33 protein in a biological sample includes contacting a biological sample from a subject with an anti-CD33 antibody or antigen-binding fragment thereof disclosed herein, and the presence of immunoreactive CD33 protein is detected in the biological sample. Detection can be accomplished by a detectable label attached to the antibody.

[0276] The term "labeled" with respect to an anti-CD33 antibody or antigen-binding fragment thereof is intended to encompass direct labeling of the antibody by coupling (i.e., physically linking) a detectable substance to the antibody, as well as indirect labeling of the antibody by reaction with another compound, such as a secondary antibody, which is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.

[0277] In certain embodiments, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein are conjugated to one or more detectable labels. For such uses, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein can be detectably labeled by covalent or non-covalent attachment of a chromogenic, enzymatic, radioisotope, isotopic, fluorescent, toxic, chemiluminescent, nuclear magnetic resonance contrast agent, or other label.

[0278] The detection methods disclosed herein can be used to detect immunoreactive CD33 protein in biological samples in vitro and in vivo. Non-limiting examples of in vitro techniques for detecting immunoreactive CD33 protein include enzyme-linked immunosorbent assay (ELISA), Western blot, immunoprecipitation, radioimmunoassay, and immunofluorescence. Additionally, in vivo techniques for detecting immunoreactive CD33 protein include introducing a labeled anti-CD33 antibody or antigen-binding fragment thereof into a subject. For example, the anti-CD33 antibody or antigen-binding fragment thereof can be labeled with a radioactive marker whose presence and location in the subject can be detected by standard imaging techniques. In certain embodiments, the biological sample contains CD33 protein molecules from the test subject.

[0279] The anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein can be used to assay immunoreactive CD33 protein levels in biological samples (e.g., human plasma) using antibody-based techniques. For example, protein expression in tissues can be studied by classical immunohistological methods. Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as enzyme-linked immunosorbent assays (ELISAs) and radioimmunoassays (RIAs). Suitable antibody assay labels are known in the art and include enzyme labels, such as glucose oxidase, and radioisotopes or other radioactive agents, such as iodine ( 125 I, 121 I, 131 I), Carbon ( 14 C), sulfur ( 35 S), tritium ( 3 H), Indium ( 111 In), and technetium ( 99m Tc), and fluorescent labels such as fluorescein, rhodamine, and green fluorescent protein (GFP), and biotin.

[0280] In addition to assaying immunoreactive CD33 protein levels in biological samples, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein can be used for in vivo imaging of CD33. Antibodies useful in this method include antibodies detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium that emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with detectable characteristic spins, such as deuterium, which can be incorporated into anti-CD33 antibodies by nutrient labeling of related scFv clones.

[0281] A suitable detectable imaging moiety (e.g., a radioisotope (e.g., 131 I, 111 I.N. 99m Tc, 18 F, 89An anti-CD33 antibody or antigen-binding fragment thereof disclosed herein labeled with a radioisotope (Zr), a radio-opaque material, or a material detectable by nuclear magnetic resonance) is introduced into a subject (e.g., parenterally, subcutaneously, or intraperitoneally). It will be understood in the art that the size of the subject and the imaging system used will determine the amount of imaging moiety required to produce a diagnostic image. In the case of a radioisotope moiety, for a human subject, the amount of radioactivity injected is typically in the range of about 5-20 millicuries. 99m The labeled anti-CD33 antibody or antigen-binding fragment thereof is then accumulated at the location of cells containing the specific target polypeptide. For example, the labeled anti-CD33 antibody or antigen-binding fragment thereof accumulates in the subject in cells and tissues where the CD33 protein is localized.

[0282] Thus, the presently disclosed subject matter provides methods for diagnosing a medical condition. In certain embodiments, the methods include (a) assaying expression of immunoreactive CD33 protein by measuring binding of an anti-CD33 antibody or antigen-binding fragment thereof disclosed herein in cells or bodily fluids of an individual, and (b) comparing the amount of immunoreactive CD33 protein present in the sample with a standard reference, where an increase or decrease in immunoreactive CD33 protein levels compared to the standard is indicative of the medical condition.

[0283] Additionally, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein may be used to purify immunoreactive CD33 protein from a sample. In certain embodiments, the antibody is immobilized on a solid support. Non-limiting examples of such solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, acrylic resins, and polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the art.

[0284] The simplest way to bind antigen to an antibody support matrix is ​​to collect the beads in a column and pass the antigen solution through the column. The efficiency of this method depends on the contact time between the immobilized antibody and the antigen, which can be extended by using a low flow rate. The immobilized antibody captures the antigen as it passes through. Alternatively, the antigen solution can be mixed with the support (e.g., beads) and the antigen can be brought into contact with the antibody-support matrix by rotating the slurry, allowing maximum contact between the antigen and the immobilized antibody. After the binding reaction is complete, the slurry is passed through the column to collect the beads. The beads are washed using a suitable washing buffer, and then the pure or substantially pure antigen is eluted.

[0285] The antibody or polypeptide of interest can be conjugated to a solid support such as beads. Furthermore, the first solid support such as beads can also be conjugated to a second solid support (which can be a second bead or other support) by any suitable means, including those disclosed herein for conjugating a polypeptide to a support, if necessary. Thus, any of the conjugation methods and means disclosed herein for conjugating a polypeptide to a solid support can be applied to the conjugation of the first support and the second support, and the first and second solid supports can be the same or different.

[0286] Suitable linkers that can be crosslinkers for use in conjugating a polypeptide to a solid support include a variety of agents that can react with functional groups present on the surface of the support, or with the polypeptide, or both. Reagents useful as crosslinkers include homo-bifunctional and especially hetero-bifunctional reagents. Useful bifunctional crosslinkers include, but are not limited to, N-SIAB, dimaleimide, DTNB, N-SATA, N-SPDP, SMCC, and 6-HYNIC. Crosslinkers can be selected to provide a selectively cleavable bond between the polypeptide and the solid support. For example, photolabile crosslinkers such as 3-amino-(2-nitrophenyl)propionic acid can be used as a means to cleave the polypeptide from the solid support. (Brown et al., Mol. Divers, pp, 4-12 (1995); Rothschild et al., Nucl. Acids Res., 24:351-66 (1996); and U.S. Pat. No. 5,643,722). Other cross-linking reagents are well known in the art (see, e.g., Wong (1991), supra, and Hermanson (1996), supra).

[0287] Antibodies or polypeptides can be immobilized on solid supports such as beads through covalent bonds formed between carboxyl-functionalized beads and the amino terminus of the polypeptide, or vice versa. In addition, bifunctional trityl linkers can be attached to supports, e.g., 4-nitrophenyl active esters on resins such as Wang resins, through amino or carboxyl groups on the resin, via amino resins. Using the bifunctional trityl approach, the solid support may require treatment with volatile acids such as formic acid or trifluoroacetic acid to ensure that the polypeptide can be cleaved and removed. In such cases, the polypeptide can be deposited as a bead-free patch on the bottom of a well of the solid support or on the flat surface of the solid support. After adding the matrix solution, the polypeptide can be desorbed by MS.

[0288] Hydrophobic trityl linkers can also be utilized as acid-labile linkers by cleaving the amino-linked trityl group from the polypeptide using a volatile acid or a suitable matrix solution, such as a matrix solution containing 3-HPA. Acid lability can also be altered. For example, trityl, monomethoxytrityl, dimethoxytrityl or trimethoxytrityl can be changed to a suitable p-substitution of the polypeptide, or a more acid-labile tritylamine derivative, i.e., trityl ether and tritylamine bonds can be created on the polypeptide. Thus, the polypeptide can be removed from the hydrophobic linker, for example, by breaking the hydrophobic attraction, or by cleaving the trityl ether or tritylamine bond under acidic conditions, if desired, under typical MS conditions, a matrix such as 3-HPA acts as an acid.

[0289] Orthogonal cleavable linkers can also be useful for binding a first solid support, e.g., a bead, to a second solid support, or for binding a polypeptide of interest to a solid support. Using such linkers, a first solid support, e.g., a bead, can be selectively cleaved from a second solid support without cleaving the polypeptide from the support, and the polypeptide can then be cleaved from the bead later. For example, a disulfide linker that can be cleaved using a reducing agent such as DTT can be used to bind the bead to the second solid support, and an acid-cleavable bifunctional trityl group can be used to immobilize the polypeptide to the support. If desired, the bond of the polypeptide to the solid support can be cleaved first, e.g., leaving the bond between the first support and the second support intact. The trityl linker can provide a covalent or hydrophobic conjugation, and regardless of the nature of the conjugation, the trityl group is easily cleaved under acidic conditions.

[0290] For example, beads can be attached to a second support via a linking group that can be selected to have a length and chemical nature to facilitate high density attachment of beads to the solid support or high density attachment of polypeptides to the beads. Such linking groups can have, for example, a "tree-like" structure, thereby providing multiple functional groups per attachment site on the solid support. Examples of such linking groups include polylysine, polyglutamic acid, penta-erythrol, and tris-hydroxy-aminomethane.

[0291] Non-covalent association. The antibody or polypeptide can be conjugated to a solid support, or the first solid support can be conjugated to a second solid support through non-covalent interactions. For example, magnetic beads made of ferromagnetic materials can be magnetized and attracted to a magnetic solid support, and can be released from the support by removing the magnetic field. Alternatively, the solid support can have ionic or hydrophobic moieties, which can respectively allow interaction with a polypeptide, for example a polypeptide containing a bound trityl group, or a second solid support with hydrophobic properties.

[0292] A solid support can also be provided with a member of a specific binding pair and thus conjugated to a polypeptide or second solid support containing the complementary binding moiety. For example, avidin or streptavidin coated beads can bind to a polypeptide having a biotin moiety incorporated therein, or a second solid support coated with biotin or a derivative of biotin, such as iminobiotin.

[0293] It should be appreciated that any of the binding members disclosed herein or otherwise known in the art can be reversed. Thus, biotin, for example, can be incorporated into either the polypeptide or the solid support, and conversely, avidin or other biotin-binding moieties would be incorporated into the support or the polypeptide, respectively. Other specific binding pairs contemplated for use herein include, but are not limited to, hormones and their receptors, enzymes and their substrates, nucleotide sequences and their complementary sequences, antibodies and the antigens with which they specifically interact, and other such pairs known to those of skill in the art.

[0294] The anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein are useful in diagnostic methods. Thus, the presently disclosed subject matter provides a method of using the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein for diagnosing CD33 activity in a subject. The anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein may be selected such that they have any level of epitope binding specificity and high binding affinity to a CD33 polypeptide.

[0295] The anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein can be used to detect immunoreactive CD33 protein in a variety of standard assay formats. Such formats include immunoprecipitation, Western blotting, ELISA, radioimmunoassay, and immunometric assays. The biological sample can be obtained from any tissue or bodily fluid of the subject. In certain embodiments, the subject is at an early stage of cancer. In certain embodiments, the early stage of cancer is determined by the level or expression pattern of CD33 protein in a sample obtained from the subject. In certain embodiments, the sample is selected from the group consisting of urine, blood, serum, plasma, saliva, amniotic fluid, cerebrospinal fluid (CSF), and biopsied body tissue.

[0296] Immunoassay or sandwich assay is one format for the diagnostic method of the present technology. Such assays use one antibody, for example, an anti-CD33 antibody or population of anti-CD33 antibodies immobilized on a solid phase, and another anti-CD33 antibody or population of anti-CD33 antibodies in solution. Typically, the solution anti-CD33 antibody or population of anti-CD33 antibodies is labeled. When an antibody population is used, the population may contain antibodies that bind to different epitope specificities within the target polypeptide. Thus, the same population can be used for both the solid phase and the solution antibody. When an anti-CD33 monoclonal antibody is used, a first and a second CD33 monoclonal antibody with different binding specificities are used in the solid phase and the solution phase. The solid phase (also called "capture") and solution (also called "detection") antibodies can be contacted with the target antigen in either order or simultaneously. If the solid phase antibody is contacted first, the assay is called a forward assay. Conversely, if the solution antibody is contacted first, the assay is called a reverse assay. If the target is contacted with both antibodies simultaneously, the assay is referred to as a simultaneous assay. After contacting the CD33 protein with the anti-CD33 antibody, the sample is incubated for a period that typically varies from about 10 minutes to about 24 hours, and typically about 1 hour. A wash step is then performed to remove components of the sample that are not specifically bound to the anti-CD33 antibody used as a diagnostic reagent. If the solid phase and solution antibodies are bound in separate steps, washing can be performed after either or both binding steps. After washing, binding is typically quantified by detecting the label linked to the solid phase through binding of the labeled solution antibody. Typically, a calibration curve is prepared from samples containing known concentrations of the target antigen for a given antibody pair or antibody population and given reaction conditions. The concentration of immunoreactive CD33 protein in the sample being tested is then read by interpolation from the calibration curve (i.e., standard curve). The analyte can be measured from the amount of labeled solution antibody bound at equilibrium, or by kinetic measurements of the bound labeled solution antibody at a series of time points before equilibrium is reached. The slope of such a curve is a measure of the concentration of CD33 protein in the sample.

[0297] Suitable supports for use in the above methods include, for example, nitrocellulose membranes, nylon membranes, and derivatized nylon membranes, as well as particles such as agarose, dextran-based gels, dipsticks, microparticles, microspheres, magnetic particles, test tubes, microtiter wells, SEPHADEX™ (Amersham Pharmacia Biotech, Piscataway NJ). Immobilization may be by absorption or by covalent attachment. Optionally, the anti-CD33 antibody can be bound to a linker molecule such as biotin for binding to a surface-bound linker such as avidin.

[0298] In certain embodiments, the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein are conjugated to a diagnostic agent. The diagnostic agent may include a radioactive or non-radioactive label, an imaging agent (such as for magnetic resonance imaging, computed tomography, or ultrasound), and the radioactive label may be a gamma, beta, alpha, auger electron, or positron emitting isotope. A diagnostic agent is a molecule that is administered conjugated to an antibody moiety, i.e., an antibody or antibody fragment, or subfragment, and is useful for diagnosing or detecting disease by locating cells that contain the antigen.

[0299] Useful diagnostic agents include, but are not limited to, radioisotopes, dyes (such as those containing biotin-streptavidin complexes), contrast agents, fluorescent compounds or molecules, and enhancement agents for magnetic resonance imaging (MRI) (e.g., paramagnetic ions). In certain embodiments, the diagnostic agent is selected from the group consisting of radioisotopes, enhancement agents for use in magnetic resonance imaging, and fluorescent compounds. Chelators may be attached to the anti-CD33 antibodies or antigen-binding fragments thereof disclosed herein using standard chemistries. Chelators are typically linked to antibodies by groups that allow for the formation of bonds to molecules with minimal loss of immunoreactivity, minimal aggregation and / or internal cross-linking.

[0300] 5.7.Kit The subject matter disclosed herein provides kits for treating or ameliorating a disease or disorder associated with CD33 (e.g., AML) and / or detecting CD33. In certain embodiments, the kit comprises an anti-CD33 antibody or antigen-binding fragment thereof, an immunoconjugate, a multispecific molecule, or a composition disclosed herein. In certain embodiments, the kit comprises a sterile container that holds a therapeutic or prophylactic vaccine, and such a container may be a box, an ampoule, a bottle, a vial, a tube, a bag, a pouch, a blister pack, or other suitable container form known in the art. Such a container may be made of plastic, glass, laminated paper, metal foil, or other material suitable for holding pharmaceutical products.

[0301] In certain embodiments, the kit further comprises instructions for administering the anti-CD33 antibodies or antigen-binding fragments thereof, immunoconjugates, multispecific molecules, or compositions disclosed herein to a subject in need of treatment. The instructions can generally include information regarding the use of the anti-CD33 antibodies or antigen-binding fragments thereof, immunoconjugates, multispecific molecules, and compositions disclosed herein to treat or ameliorate a disease or disorder. In certain embodiments, the instructions include at least one of the following: description of the therapeutic agent, dosing schedules and administration for treatment and / or prevention of a tumor or neoplasm or symptoms thereof, precautions, warnings, indications, counterindications, overdose information, adverse reactions, animal pharmacology, clinical studies, and / or references. The instructions can be printed directly on the container (if present), as a label applied to the container, or as a separate sheet, pamphlet, card, or folder supplied in or with the container.

[0302] 5.8. Illustrative Embodiments A1. In certain non-limiting embodiments, the presently disclosed subject matter provides anti-CD33 antibodies, or antigen-binding fragments thereof, comprising a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:18, SEQ ID NO:28, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:72, SEQ ID NO:81, or SEQ ID NO:88.

[0303] A2. In certain non-limiting embodiments, the presently disclosed subject matter provides an anti-CD33 antibody, or antigen-binding fragment thereof, comprising a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:19, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:63, SEQ ID NO:73, SEQ ID NO:82, SEQ ID NO:89, or SEQ ID NO:92.

[0304] A3. In certain non-limiting embodiments, the subject matter of the present disclosure comprises: (a) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:18, SEQ ID NO:28, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:72, SEQ ID NO:81, or SEQ ID NO:88; and (b) an anti-CD33 antibody, or antigen-binding fragment thereof, comprising a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:19, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:63, SEQ ID NO:73, SEQ ID NO:82, SEQ ID NO:89, or SEQ ID NO:92.

[0305] A4. In certain non-limiting embodiments, the subject matter of the present disclosure is an anti-CD33 antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region are: (a) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:8, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:9; (b) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:18, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:19; (c) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:28, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:29; (d) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:35, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:29; (e) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:43, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:44; (f) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:52, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:53; (g) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:62, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:63; (h) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 72, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 73; (i) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 81, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 81; (j) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:88, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:89; and (k) an anti-CD33 antibody or antigen-binding fragment thereof selected from the group consisting of a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:8, and a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:92.

[0306] A5. In certain non-limiting embodiments, the presently disclosed subject matter provides an anti-CD33 antibody, or antigen-binding fragment thereof, comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:18, SEQ ID NO:28, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:72, SEQ ID NO:81, or SEQ ID NO:88.

[0307] A6. In certain non-limiting embodiments, the presently disclosed subject matter provides an anti-CD33 antibody, or antigen-binding fragment thereof, comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:19, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:63, SEQ ID NO:73, SEQ ID NO:82, SEQ ID NO:89, or SEQ ID NO:92.

[0308] A7. In certain non-limiting embodiments, the subject matter of the present disclosure comprises: (a) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:18, SEQ ID NO:28, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:72, SEQ ID NO:81, or SEQ ID NO:88; and (b) an anti-CD33 antibody, or antigen-binding fragment thereof, comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:19, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:63, SEQ ID NO:73, SEQ ID NO:82, SEQ ID NO:89, or SEQ ID NO:92;

[0309] A8. (a) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:8 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:9; or (b) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 18 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 19; or (c) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:28 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:29; or (d) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 35 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 29; or (e) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 43 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 44; or (f) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:52 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:53; or (g) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:62 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:63; or (h) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 72 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 73; or (i) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 81 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 82; or (j) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 88 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 89; or (k) The antibody or antigen-binding fragment thereof according to any one of A1 to A7, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 98 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 92.

[0310] A9. (a) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:8 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:9; or (b) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 18 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 19; or (c) The anti-CD33 antibody or antigen-binding fragment thereof described in A8, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 28 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 29.

[0311] A10. In certain non-limiting embodiments, the subject matter of the present disclosure is an anti-CD33 antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising a CDR1 domain, a CDR2 domain, and a CDR3 domain, and a light chain variable region comprising a CDR1 domain, a CDR2 domain, and a CDR3 domain, wherein the CDR3 domain of the heavy chain variable region and the light chain variable region are (a) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 4 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7 or a conservative modification thereof; (b) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17 or a conservative modification thereof; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27 or a conservative modification thereof; (d) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27 or a conservative modification thereof; (e) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42 or a conservative modification thereof; (f) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 51 or a conservative modification thereof; (g) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 58 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 61 or a conservative modification thereof; (h) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71 or a conservative modification thereof; (i) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 77 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 80 or a conservative modification thereof; or (j) An anti-CD33 antibody or an antigen-binding fragment thereof is provided, the antibody or fragment thereof being selected from the group consisting of a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 87 or a conservative modification thereof, and a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42 or a conservative modification thereof.

[0312] A11. The heavy chain variable region and the light chain variable region CDR2 domain are (a) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 3 or a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6 or a conservative modification thereof; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13 or a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16 or a conservative modification thereof; (c) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23 or a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26 or a conservative modification thereof; (d) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26 or a conservative modification thereof; (e) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41 or a conservative modification thereof; (f) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 50 or a conservative modification thereof; (g) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57 or a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 60 or a conservative modification thereof; (h) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 67 or a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70 or a conservative modification thereof; (i) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57 or a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 79 or a conservative modification thereof; and (j) The antibody or antigen-binding fragment thereof described in A10, wherein the antibody or antigen-binding fragment thereof is selected from a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86 or a conservative modification thereof, and a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41 or a conservative modification thereof.

[0313] A12. The CDR1 domain of the heavy chain variable region and the light chain variable region is (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2 or a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5 or a conservative modification thereof; (b) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12 or a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15 or a conservative modification thereof; (c) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22 or a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25 or a conservative modification thereof; (d) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32 or a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25 or a conservative modification thereof; (e) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 40 or a conservative modification thereof; (f) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 47 or a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 49 or a conservative modification thereof; (g) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 56 or a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 59 or a conservative modification thereof; (h) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 66 or a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69 or a conservative modification thereof; (i) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 76 or a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 78 or a conservative modification thereof; or (j) The antibody or antigen-binding fragment thereof according to A10 or A11, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 86 or a conservative modification thereof, and a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5 or a conservative modification thereof.

[0314] A13. An antibody or antigen-binding fragment thereof according to any one of A10 to A12, wherein one or more of the CDR sequences have up to about 5 amino acid substitutions.

[0315] A14. An antibody or antigen-binding fragment thereof according to any one of A10 to A13, wherein one or more of the CDR sequences have up to about three amino acid substitutions.

[0316] A15. In certain non-limiting embodiments, the subject matter of the present disclosure comprises: (a) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 3, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 4; (b) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14; (c) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24; (d) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; (e) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39; (f) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 47, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48; (g) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 56, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 58; (h) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 66, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 67, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68; (i) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 76, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 77; or (j) An anti-CD33 antibody or antigen-binding fragment thereof is provided, comprising a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 85, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 87.

[0317] A16. In certain non-limiting embodiments, the subject matter of the present disclosure comprises: (a) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:6, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:7; (b) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17; (c) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27; (d) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 40, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42; (e) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 49, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 50, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 51; (f) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 59, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 60, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 61; (g) a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; (h) a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 78, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 79, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 80; or (i) An anti-CD33 antibody or antigen-binding fragment thereof is provided, comprising a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO:5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO:41, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:42.

[0318] A17. In certain non-limiting embodiments, the subject matter of the present disclosure comprises: (a) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 3, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 4, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7; (b) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17; (c) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27; (d) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27; (e) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 40, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42; (f) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 47, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 49, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 50, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 51; (g) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 56, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 58, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 59, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 60, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 61; (h) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 66, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 67, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; (i) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 76, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 77, and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 78, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 79, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 80; or (j) An anti-CD33 antibody or antigen-binding fragment thereof is provided, comprising a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 85, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 87, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42.

[0319] A18. (a) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 3, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 4, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7; (b) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14, and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17; or (c) The antibody or antigen-binding fragment thereof described in A17, which is a heavy chain variable region comprising CDR1 having the amino acid sequence set forth in SEQ ID NO: 22, CDR2 having the amino acid sequence set forth in SEQ ID NO: 23, and CDR3 having the amino acid sequence set forth in SEQ ID NO: 24, and a light chain variable region comprising CDR1 having the amino acid sequence set forth in SEQ ID NO: 25, CDR2 having the amino acid sequence set forth in SEQ ID NO: 26, and CDR3 having the amino acid sequence set forth in SEQ ID NO: 27.

[0320] A19. The antibody or antigen-binding fragment according to any one of A1 to A18, wherein the antibody comprises a heavy chain constant region and / or a light chain constant region.

[0321] A20. (a) the heavy chain constant region comprises an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 95; and / or (b) The antibody or antigen-binding fragment thereof described in A19, wherein the light chain constant region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 96.

[0322] A21. (a) the heavy chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 95; and / or (b) The antibody or antigen-binding fragment thereof described in A19 or A20, wherein the light chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 96 or SEQ ID NO: 99.

[0323] A22. The antibody or antigen-binding fragment thereof is (a) a heavy chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:97, SEQ ID NO:100, or SEQ ID NO:102; and / or (b) The antibody or antigen-binding fragment thereof according to any one of A1 to A21, comprising a light chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 98, SEQ ID NO: 101, or SEQ ID NO: 103.

[0324] A23. The antibody or antigen-binding fragment thereof is (a) a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 97, SEQ ID NO: 100, or SEQ ID NO: 102, and / or (b) The antibody or antigen-binding fragment thereof according to any one of A1 to A21, which comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 98, SEQ ID NO: 101, or SEQ ID NO: 103.

[0325] A24. The antibody or antigen-binding fragment thereof according to any one of A1 to A23, wherein the antibody or antigen-binding fragment thereof binds to CD33 and comprises the amino acid sequence set forth in SEQ ID NO: 215 or a fragment thereof.

[0326] A25. The antibody or antigen-binding fragment thereof according to any one of A1 to A24, wherein the antibody comprises a human variable region framework region.

[0327] A26. The antibody or antigen-binding fragment thereof according to any one of A1 to A25, which is fully human or an antigen-binding fragment thereof.

[0328] A27. The antibody or antigen-binding fragment thereof according to any one of A1 to A24, which is a chimeric antibody or an antigen-binding fragment thereof.

[0329] A28. The antibody or antigen-binding fragment thereof according to any one of A1 to A24, which is a humanized antibody or an antigen-binding fragment thereof.

[0330] A29. The antibody or antigen-binding fragment thereof according to any one of A1 to A28, wherein the antigen-binding fragment is Fab, Fab', F(ab')2, a variable fragment (Fv), or a single-chain variable region (scFv).

[0331] A30. The antibody or antigen-binding fragment thereof according to A29, wherein the antigen-binding fragment is an scFv.

[0332] A31. In certain non-limiting embodiments, the subject matter disclosed herein provides an antibody, or antigen-binding fragment thereof, that cross-competes with an antibody, or antigen-binding fragment thereof, described in any one of A1-A30, for binding to CD33.

[0333] A32. In certain non-limiting embodiments, the subject matter disclosed herein provides an antibody or antigen-binding fragment thereof that binds to the same epitope region on CD33 as an antibody or antigen-binding fragment thereof described in any one of claims A1-A30.

[0334] B1. In certain non-limiting embodiments, the presently disclosed subject matter provides a composition comprising an antibody or antigen-binding fragment thereof according to any one of A1-A32.

[0335] B2. The composition of B1, which is a pharmaceutical composition further comprising a pharma- ceutically acceptable carrier.

[0336] C1. In certain non-limiting embodiments, the presently disclosed subject matter provides an immunoconjugate comprising an antibody or antigen-binding fragment thereof described in any one of A1-A32, linked to a therapeutic agent.

[0337] C2. The immunoconjugate of C1, wherein the therapeutic agent is a drug, a cytotoxin, or a radioisotope.

[0338] D1. In certain non-limiting embodiments, the presently disclosed subject matter provides a composition comprising an immunoconjugate described in C1 or C2.

[0339] D2. The composition of D1, which is a pharmaceutical composition further comprising a pharma- ceutically acceptable carrier.

[0340] E1. In certain non-limiting embodiments, the subject matter disclosed herein provides a multispecific molecule comprising an antibody or antigen-binding fragment thereof according to any one of A1-A32, linked to one or more functional moieties.

[0341] E2. The multispecific molecule of E2, wherein one or more functional moieties have a binding specificity different from that of an antibody or antigen-binding fragment thereof.

[0342] F1. In certain non-limiting embodiments, the presently disclosed subject matter provides compositions comprising a multispecific molecule as described in E1 or E2.

[0343] F2. The composition of F1, which is a pharmaceutical composition further comprising a pharma- ceutically acceptable carrier.

[0344] G1. In certain non-limiting embodiments, the presently disclosed subject matter provides a nucleic acid encoding an antibody or antigen-binding fragment thereof according to any one of A1-A32.

[0345] G2. In certain non-limiting embodiments, the subject matter disclosed herein provides a nucleic acid encoding a heavy chain variable region of an antibody or antigen-binding fragment thereof described in any one of A1 to A32.

[0346] G3. The nucleic acid of G2, comprising a nucleotide sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the nucleotide sequence set forth in SEQ ID NO:10, SEQ ID NO:20, SEQ ID NO:30, SEQ ID NO:36, SEQ ID NO:45, SEQ ID NO:54, SEQ ID NO:64, SEQ ID NO:74, SEQ ID NO:83, SEQ ID NO:90, or SEQ ID NO:93.

[0347] G4. The nucleic acid of G2 or G3, comprising the nucleotide sequence set forth in SEQ ID NO:10, SEQ ID NO:20, SEQ ID NO:30, SEQ ID NO:36, SEQ ID NO:45, SEQ ID NO:54, SEQ ID NO:64, SEQ ID NO:74, SEQ ID NO:83, SEQ ID NO:90, or SEQ ID NO:93.

[0348] G5. In certain non-limiting embodiments, the subject matter disclosed herein provides a nucleic acid encoding a light chain variable region of an antibody or antigen-binding fragment thereof described in any one of A1 to A32.

[0349] G6. The nucleic acid of G5, comprising a nucleotide sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the nucleotide sequence set forth in SEQ ID NO:11, SEQ ID NO:21, SEQ ID NO:31, SEQ ID NO:46, SEQ ID NO:55, SEQ ID NO:65, SEQ ID NO:75, SEQ ID NO:84, SEQ ID NO:91, or SEQ ID NO:94.

[0350] G7. The nucleic acid of G6 or G7, comprising the nucleotide sequence set forth in SEQ ID NO:11, SEQ ID NO:21, SEQ ID NO:31, SEQ ID NO:46, SEQ ID NO:55, SEQ ID NO:65, SEQ ID NO:75, SEQ ID NO:84, SEQ ID NO:91, or SEQ ID NO:94.

[0351] H1. In certain non-limiting embodiments, the subject matter disclosed herein provides a vector comprising a nucleic acid described in any one of G1-G7.

[0352] J1. In certain non-limiting embodiments, the presently disclosed subject matter provides a host cell comprising a vector described in H1.

[0353] K1. In certain non-limiting embodiments, the subject matter disclosed herein is a method for detecting CD33 in a whole cell, tissue, or blood sample, comprising: contacting a cell, tissue or blood sample with the antibody or antigen-binding fragment thereof according to any one of A1 to A32, wherein the antibody or antigen-binding fragment thereof comprises a detectable label; determining the amount of labeled antibody or antigen-binding fragment thereof bound to the cell, tissue or blood sample by measuring the amount of detectable label associated with the cell or tissue, wherein the amount of bound antibody or antigen-binding fragment thereof indicates the amount of CD33 in the cell, tissue or blood sample.

[0354] L1. In certain non-limiting embodiments, the subject matter disclosed herein provides a method of treating or ameliorating a disease or disorder associated with CD33 in a subject, the method comprising administering to the subject an antibody or antigen-binding fragment thereof described in any one of A1-A32, an immunoconjugate described in C1 or C2, a multispecific molecule described in E1 or E2, or a composition described in any one of B1, B2, D1, D2, F1, and F2.

[0355] L2. The method of L1, wherein the disease or disorder is a tumor.

[0356] L3. In certain non-limiting embodiments, the subject matter disclosed herein provides a method of reducing tumor burden in a subject, comprising administering to the subject an antibody or antigen-binding fragment thereof described in any one of A1-A32, an immunoconjugate described in C1 or C2, a multispecific molecule described in E1 or E2, or a composition described in any one of B1, B2, D1, D2, F1, and F2.

[0357] L4. The method of L3, wherein the method reduces the number of tumor cells, reduces tumor size, and / or eradicates tumor in the subject.

[0358] L5. In certain non-limiting embodiments, the subject matter disclosed herein provides a method of treating and / or preventing a tumor in a subject comprising administering to the subject an antibody or antigen-binding fragment thereof described in any one of A1-A32, an immunoconjugate described in C1 or C2, a multispecific molecule described in E1 or E2, or a composition described in any one of B1, B2, D1, D2, F1, and F2.

[0359] L6. In certain non-limiting embodiments, the subject matter disclosed herein provides a method of increasing or extending survival time of a subject bearing a tumor comprising administering to the subject an antibody or antigen-binding fragment thereof described in any one of A1-A32, an immunoconjugate described in C1 or C2, a multispecific molecule described in E1 or E2, or a composition described in any one of B1, B2, D1, D2, F1, and F2.

[0360] L7. The method of L6, wherein the method reduces or eradicates tumor burden in the subject.

[0361] L8. The method according to any one of L1 to L7, wherein the tumor is cancer.

[0362] L9. The method of any one of L1-L8, wherein the tumor is a blood cancer or a solid tissue cancer.

[0363] L10. The method of L9, wherein the hematological cancer is selected from the group consisting of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), myeloproliferative neoplasms (MPN), and chronic myeloid neoplasms.

[0364] L11. The method of L10, wherein the blood cancer is acute myeloid leukemia (AML).

[0365] L12. The method of any one of L1 to L11, wherein the subject is a human.

[0366] M1. In certain non-limiting embodiments, the subject matter disclosed herein provides kits for treating or ameliorating a disease or disorder in a subject, reducing tumor burden in a subject, treating and / or preventing a tumor in a subject, and / or increasing or extending survival time of a subject having a tumor, the kit comprising an antibody or antigen-binding fragment thereof described in any one of A1-A32, an immunoconjugate described in C1 or C2, a multispecific molecule described in E1 or E2, or a composition described in any one of B1, B2, D1, D2, F1, and F2.

[0367] M2. The kit of Claim 65, wherein the kit further comprises written instructions for using the antibody or antigen-binding fragment thereof, immunoconjugate, multispecific molecule, or composition to treat or ameliorate a disease or disorder in a subject, to treat or ameliorate a disease or disorder in a subject, to reduce tumor burden in a subject, to treat and / or prevent a tumor in a subject, and / or to increase or prolong survival time of a subject bearing a tumor. EXAMPLES

[0368] 6. Working Example The following examples are presented to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the antibodies, multispecific antibodies, compositions comprising them, screening, and treatment methods of the presently disclosed subject matter, and are not intended to limit the scope of what the inventors regard as the presently disclosed subject matter. It will be understood that various other embodiments may be practiced given the general description provided above.

[0369] Example 1 - Generation of anti-CD33 antibodies and scFvs disclosed herein Summary of lead identification. Antibody generation was performed by immunizing AlivaMab® mice (Ablexis) with CD33-encoding plasmid DNA and commercially or in-house produced recombinant protein. Hybridomas were generated by electrofusion and supernatants were screened by enzyme-linked immunosorbent assay (ELISA) on the recombinant protein and by flow cytometry on cells overexpressing CD33 and AML cell lines with endogenous CD33 expression. After completion of subcloning and sequencing, seven unique monoclonal antibodies (mAbs) were identified. Two antibodies bound to the IgC2 domain and five to the IgV domain. Variable heavy chains (VH) formatted into single-chain fragment variable (scFv) domains were identified. H ) and variable light chain (V L ) sequences were used as building blocks to generate chimeric antigen receptors (CARs).

[0370] The 3-P14 and 4-B2 antibodies were selected as the top lead candidates based on the following biological and functional properties. Membrane-proximal epitopes (IgC2 domains) Potent binding to a range of AML lines with single- to double-digit nM EC50

[0371] One additional antibody, 1J19, targeting the membrane-distal IgV domain, also showed superior potency compared to the reference antibody, and as a result, this clone was included as a backup molecule.

[0372] Antibody generation. Recombinant human CD33 protein was commercially available from R&D Systems and Acro Biosystems. Mouse and cynomolgus CD33 proteins were purchased from Sino Biological. The extracellular domain (ECD) of human CD33 (residues 18-259, European Nucleotide Archive #AAA51948) fused via its carboxy terminus to human IgG1 Fc or 6xHis tag, as well as cynomolgus CD33 (residues 35-275) and mouse CD33 (residues 18-240) fused via their carboxy termini to 6xHis tag were used. In addition, human CD33 IgC2-type domain (residues 140-259) with terminal mouse IgG1 Fc or 6xHis tag was produced at LakePharma.

[0373] DNA encoding the human CD33 IgC2 extracellular domain or IgC2 followed by the CD33 transmembrane segment was cloned into a vector for DNA immunization. All protein and DNA reagents were subjected to rigorous quality control before use for antibody generation, screening and characterization. Multiple cohorts of AlivaMab® mice were immunized with recombinant protein or plasmid DNA encoding the CD33 IgC2-type domain, as shown in Table 13. The immunization approach for cohorts 2 and 3 was aimed at developing cross-reactive antibodies, whereas the strategy for cohorts 4-6 was designed to generate membrane proximal domain antibodies. Complete Freund's adjuvant (CFA) was used for prime injections, followed by 8-12 boosts with TiterMax or RIBI over a period of 28-34 days. Proteins were administered via the knee route, while DNA was injected into the tail vein. [Table 13]

[0374] Serum was collected on days 17, 24, 28, and 31 and immune responses were analyzed by ELISA using recombinant human CD33 ECD-6xHis and CD33 IgC2-6xHis proteins. Mice from cohorts 1, 2, and 4 developed midpoint titers of greater than 1:10,000 and were selected for final boost, hybridoma generation, and screening.

[0375] Three days after the final boost, lymph nodes were harvested and pooled for each cohort, followed by isolation of IgG-producing B cells by magnetic sorting. Enriched B cells were electrofused with mouse myeloma cells to generate hybridomas, which were plated for screening.

[0376] Hybridoma screening. Hybridoma supernatants were analyzed by screening. Binding to human CD33 (full ECD and IgC2), cynomolgus monkey and mouse CD33 was analyzed by ELISA. Tertiary screening was performed by flow cytometry utilizing cells stably overexpressing human CD33 (NIH-3T3 full length and IgC2 domain only) and an AML cell line (U937) that endogenously expresses CD33. NALM6 cells, which are CD33 negative, were used to test non-specific binding.

[0377] Primary screening by ELISA using soluble His-tagged human CD33 (full length and IgC2) yielded 96 hits. Secondary screening using human, cynomolgus and mouse CD33 yielded 53 confirmed binders. In addition, 18 clones were cross-reactive with cynomolgus CD33 and 3 supernatants showed weak binding to mouse CD33. All 53 confirmed supernatants were tested for binding to CD33 in its native membrane-bound form on 3T3 cells overexpressing human CD33 (full length or IgC2 domain). Furthermore, 31 supernatants gave signals above background on these cells and 5 clones targeted the IgC2 domain. Binding was tested on AML cell lines U937 and Set2. All 31 clones were confirmed on these AML lines.

[0378] Upon completion of the binding and cross-reactivity experiments shown in the screening funnel, ten hybridomas were selected for subcloning. These included four antibodies that were cross-reactive with cynomolgus CD33, and three antibodies specific for the IgC2 domain. All ten clones showed consistent binding when tested by ELISA (see Table 14) or overexpression and flow cytometry with AML lines (see Table 15). [Table 14] [Table 15]

[0379] Subcloning. Subcloning was performed by limiting dilution. Four subclones of each parental hybridoma were selected and tested by flow cytometry using 3T3 CD33, 3T3 CD33-IgC2, 3T3 parental, U937 and NALM6 cell lines.

[0380] Example 2 - Binding Characterization of Anti-CD33 Antibodies Disclosed herein One subclone from each parent antibody was selected and purified from 30 ml hybridoma supernatant cultures using Protein G or Protein A, depending on the mouse IgG isotype subclass. Purified antibodies were characterized by FACS and ELISA as follows. ELISA binding to huCD33(ECD)-His and moCD33(ECD)-His, FACS binding to huCD33(FL)-3T3, U937 and U937 hCD33KO cells, and FACS EC50 on two different CD33 positive AML lines (U937 and Set2; see Figure 2 and Table 16) [Table 16]

[0381] To establish a target candidate profile (TCP), H -V L The scFv orientations 3P14 and 4B2 (referred to as "TDI-Y-006" and "TDI-Y-007", respectively) and 1J19 were selected. The targets were tested in a series of in vitro binding and functional assays. For binding studies, the antibodies were recombinantly produced with a human IgG1 constant region. The antibody H195 (lintuzumab) was included as a reference for comparison.

[0382] TDI-Y-006 and TDI-Y-007 have single-digit nM affinities (K D TDI-Y-006 and TDI-Y-007 bound to recombinant human CD33 in solution with EC50 values ​​of 6.54 nM and 17 nM, respectively, which overexpress CD33. Furthermore, TDI-Y-006 and TDI-Y-007 bound to U937 cells, a human AML cell line that endogenously expresses CD33, with EC50 values ​​of 8.5 nM and 45 nM, respectively.

[0383] Binding to recombinant CD33 protein. Binding to CD33 protein was performed by ELISA using human CD33-His (full length or IgC2 domain), cynomolgus monkey CD33-His, and mouse CD33-His. 5 μg / mL of recombinant protein was captured by pre-blocked Ni-NTA plate. Candidate antibodies were added in triplicate at 10 μg / mL and detected using horseradish peroxidase (HRP)-conjugated anti-human Fc antibody. As shown in FIG. 3, TDI-Y-006 and TDI-Y-007 bound to both human CD33 ECD and IgC2 domain protein. No binding to cynomolgus monkey or mouse CD33 was detected for either TDI-Y-006 or TDI-Y-007. 1J19 and H195 bound only to full-length human CD33 ECD, but not to IgC2, as these antibodies target the IgV domain. 1J19 showed a moderate level of cross-reactivity to cynoCD33.

[0384] Binding affinity to human CD33 protein was measured by biolayer interferometry (BLI) using Octet Red96e. All experiments were performed using kinetic buffer (PBS pH 7.4, 0.01% BSA, 0.002% Tween®-20). Antibodies were captured by anti-huFc biosensors and a 7-point, 2-fold dilution series of huCD33-His was used as the analyte. Data were processed by double reference subtraction and response curves were globally fitted to a 1:1 Langmuir binding model. The results are shown in Table 17 below. TDI-Y-006, TDI-Y-007, and 1J19 have dissociation constants (K D ) with slight changes in on- and off-rates. The binding affinity is similar to the H195 reference antibody. [Table 17]

[0385] Binding affinity to cynomolgus CD33 was also measured by BLI using Octet Red96e as described above. None of the antibodies, including H195, showed binding to cynomolgus CD33 at a concentration of 500 nM.

[0386] Binding to CD33 on cells. To evaluate the binding of TDI-Y-006, TDI-Y-007 and 1J19 to cell surface-bound CD33, 3T3 cells overexpressing CD33 and U937 AML cell line expressing endogenous CD33 were used. U937 CD33KO or NALM6 were included as negative controls. Briefly, NALM6, U937 CD33 + and KO cells were blocked with human IgG Fc for 20 min on ice. Recombinant antibodies were then added in serial dilutions starting at a concentration of 100 μg / mL for 30 min on ice. AlexaFluor647-conjugated goat anti-human F(ab')2 was added to cells for 30 min on ice, washed, and analyzed by flow cytometry and normalized to secondary only staining (MFI ratio). EC50 values ​​were determined by nonlinear regression.

[0387] TDI-Y-006 bound to 3T3-CD33 overexpressing cells and U937 cells with EC50 values ​​of 5 nM and 8.5 nM, respectively. TDI-Y-007 bound to 3T3-CD33 and U937 cells with EC50 values ​​of 17 nM and 45 nM, respectively. 1J19 and H195 bound to 3T3-CD33 and U937 cells with EC50 values ​​in the single-digit nM range (Figures 4A and 4B and Table 18). No binding was observed with NALM6 (CD33 negative) or U937CD33KO at 666 nM (data not shown). [Table 18]

[0388] K in solution DA 40-fold difference between the K and EC50 on cells was observed for TDI-Y-007. The epitope for this antibody may be in close proximity to the cell membrane and therefore less accessible on cells than the soluble protein. K within 5-7 fold D and EC50 values, distinct from that of TDI-Y-007 (see below), may be located in a part of the IgC2 domain that is equally accessible both in the recombinant protein and on the cell surface.

[0389] Epitope binning. Epitope binning was performed by BLI competition experiments using Octet Red96e. Human CD33-His was captured by anti-penta-His biosensor. 4x4 matrices with TDI-Y-006, TDI-Y-007, 1J19 and H195 were tested. A reference biosensor was used to determine the overall capture level for each antibody. Antibodies were pre-bound at saturating levels, and then the biosensor was immersed in the antibody solution to evaluate competition. The data are shown in Table 19. When TDI-Y-007 was pre-bound, TDI-Y-006 still showed significant capture. However, when TDI-Y-006 was pre-bound, the binding of TDI-Y-007 was blocked. This suggests that TDI-Y-006 and TDI-Y-007 have epitopes that are close or partially overlapping but not identical. Similarly, 1J19 and H195 have partially overlapping epitopes. No competition was observed between antibodies binding to the membrane proximal IgC2 domain (TDI-Y-006 and TDI-Y-007) and antibodies binding to the membrane distal IgV domain (1J19 and H195). [Table 19]

[0390] A summary of the characteristics of the TDI-Y-006 and TDI-Y-007 antibodies is shown in Table 20 below. [Table 20]

[0391] Embodiments of the subject matter disclosed herein From the foregoing description, it will be apparent that variations and modifications may be made to the subject matter disclosed herein to adapt it to various usages and conditions. Such embodiments are within the scope of the following claims.

[0392] The recitation of a list of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of the listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.

[0393] All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each individual patent and publication was specifically and individually indicated to be incorporated by reference.

Claims

1. (a) a heavy chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:18, SEQ ID NO:28, SEQ ID NO:35, SEQ ID NO:43, SEQ ID NO:52, SEQ ID NO:62, SEQ ID NO:72, SEQ ID NO:81, or SEQ ID NO:88; and / or (b) an anti-CD33 antibody or antigen-binding fragment thereof, comprising a light chain variable region comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:9, SEQ ID NO:19, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:63, SEQ ID NO:73, SEQ ID NO:82, SEQ ID NO:89, or SEQ ID NO:

92.

2. (a) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 8 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 9; or (b) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 18 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 19; or (c) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:28 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:29; or (d) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 35 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 29; or (e) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 43 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 44; or (f) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 52 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 53; or (g) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 62 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 63; or (h) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 72 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 73; or (i) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 81 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 82; or (j) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 88 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 89; or (k) The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 98 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:

92.

3. (a) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 2, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 3, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 4, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7; (b) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 13, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 14, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 15, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 16, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 17; (c) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27; (d) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27; (e) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 40, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42; (f) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 47, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 49, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 50, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 51; (g) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 56, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 58, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 59, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 60, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 61; (h) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 66, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 67, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68; and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; (i) a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 76, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 77, and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 78, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 79, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 80; or (j) An anti-CD33 antibody or antigen-binding fragment thereof comprising: a heavy chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 85, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 87; and a light chain variable region comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41, and CDR3 comprising the amino acid sequence set forth in SEQ ID NO:

42.

4. The antibody or antigen-binding fragment of any one of claims 1 to 3, wherein the antibody comprises a heavy chain constant region and / or a light chain constant region.

5. (a) the heavy chain constant region comprises an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 95; and / or (b) The antibody or antigen-binding fragment thereof of claim 4, wherein the light chain constant region comprises an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:

96.

6. (a) the heavy chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 95; and / or (b) The antibody or antigen-binding fragment thereof of claim 4, wherein the light chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 96 or SEQ ID NO:

99.

7. the antibody or antigen-binding fragment thereof (a) a heavy chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:97, SEQ ID NO:100, or SEQ ID NO:102; and / or (b) the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, comprising a light chain comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO:98, SEQ ID NO:101, or SEQ ID NO:

103.

8. the antibody or antigen-binding fragment thereof (a) a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 97, SEQ ID NO: 100, or SEQ ID NO: 102, and / or (b) an antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, comprising a light chain comprising the amino acid sequence set forth in SEQ ID NO: 98, SEQ ID NO: 101, or SEQ ID NO:

103.

9. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein the antibody comprises human variable region framework regions.

10. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, which is fully human or an antigen-binding fragment thereof.

11. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, which is a chimeric antibody or antigen-binding fragment thereof.

12. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, which is a humanized antibody or antigen-binding fragment thereof.

13. The antigen-binding fragment may be Fab, Fab', F(ab') ２ 4. The antibody or antigen-binding fragment thereof according to claim 1, which is a single-chain variable region (scFv), a variable fragment (Fv), or a single-chain variable region (scFv).

14. The antibody or antigen-binding fragment thereof of claim 13, wherein the antigen-binding fragment is an scFv.

15. An immunoconjugate comprising the antibody or antigen-binding fragment thereof of any one of claims 1 to 3 linked to a therapeutic agent.

16. A multispecific molecule comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3 linked to one or more functional moieties.

17. A composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1 to 3, an immunoconjugate comprising said antibody or antigen-binding fragment thereof linked to a therapeutic agent, or a multispecific molecule comprising said antibody or antigen-binding fragment thereof linked to one or more functional moieties.

18. A nucleic acid encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3.

19. A vector comprising the nucleic acid of claim 18.

20. A host cell comprising the vector of claim 19.

21. 10. A composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1 to 3 for use in a method for detecting CD33 in a whole cell, tissue, or blood sample, the method comprising: contacting a cell, tissue or blood sample with the antibody or antigen-binding fragment thereof of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment thereof comprises a detectable label; determining the amount of labeled antibody or antigen-binding fragment thereof bound to the cells, tissue or blood sample by measuring the amount of detectable label associated with the cells or tissue, wherein the amount of bound antibody or antigen-binding fragment thereof indicates the amount of CD33 in the cells, tissue or blood sample.

22. The composition of claim 17 for use in treating or ameliorating a CD33-related disease or disorder in a subject, treating and / or preventing a tumor in a subject, and / or increasing or extending the survival time of a subject with a tumor.

23. 23. The composition of claim 22, wherein the disease or tumor is selected from the group consisting of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), myeloproliferative neoplasm (MPN), and chronic myeloid neoplasm.

24. 10. A kit for treating or ameliorating a disease or disorder in a subject, for reducing tumor burden in a subject, for treating and / or preventing a tumor in a subject, and / or for increasing or prolonging survival time of a subject bearing a tumor, comprising the antibody or antigen-binding fragment thereof of any one of claims 1 to 3, an immunoconjugate comprising said antibody or antigen-binding fragment thereof linked to a therapeutic agent, or a multispecific molecule comprising said antibody or antigen-binding fragment thereof linked to one or more functional moieties.

Images